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Abstract 
Neuroblastoma is a childhood cancer of the developing nervous system 
caused by dysregulated proliferation of neural crest cells. Differentiation agents 
are used as standard treatment to induce the regression of neuroblastoma 
tumours. The ability of some neuroblastomas to spontaneously differentiate 
correlates with a high expression of the neuronal tyrosine kinase N2-Src. 
Furthermore, N2-Src is able to induce differentiation of neuroblastoma cell lines, 
providing insights for novel differentiation treatments. Our laboratory generated 
preliminary data suggesting that N2-Src overexpression increases tyrosine 
phosphorylation of a complex that includes proteins of the COPII coat. The COPII 
complex plays an essential role in the early secretory pathway by coordinating 
vesicle trafficking from the endoplasmic reticulum to the Golgi apparatus. In this 
study I investigated the role of the COPII complex in neuroblastoma differentiation 
downstream of N2-Src. Our hypothesis is that tyrosine phosphorylation of COPII 
coat components by N2-Src directs the transport of cargoes that promote 
differentiation of neuroblastoma cells. I demonstrated that N2-Src interacts with 
different components of the COPII complex, and that the overexpression of N2-Src 
specifically increases tyrosine phosphorylation of the COPII coat component 
Sec23A in HeLa cells. Interestingly, overexpressed N2-Src in COS7 cells is 
located in perinuclear endosomal structures and induces the redistribution of ER-
exit sites, where the formation of COPII vesicles is initiated. Finally, I observed 
inhibition of N2-Src induced neurite outgrowth by the overexpression of COPII 
components in fibroblast and neuroblastoma cells. Together, these data implicate 
COPII traffic in N2-Src induced neuroblastoma differentiation and provide insight 
for the development of novel differentiation treatments. 
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Chapter 1. Introduction 
1.1 Neuroblastoma 
Neuroblastoma is a rare childhood cancer that arises during foetal or early 
postnatal nervous system development for which therapeutic progress has been 
slow. The incidence of neuroblastoma is 1 per 8,000-10,000 births and it is 
responsible for 15 % of paediatric cancer deaths (Maris et al., 2007). 
Neuroblastoma cells derive from neuroblasts of the neural crest that migrate to the 
foetal adrenal or the sympathetic ganglion and stay in an undifferentiated state, 
forming a tumour. The outcome of neuroblastoma is very heterogeneous: some 
tumours undergo spontaneous regression caused by neuronal differentiation 
and/or cellular apoptosis, whereas others are aggressive and therapy-resistant 
(Cheung and Dyer, 2013). Low-risk neuroblastoma is usually removed by surgery, 
but high-risk neuroblastoma requires multimodal therapy that includes 
chemotherapy, administration of differentiation agents and immunotherapy, with 
only 40 % survival (Hara, 2012). One of the main factors influencing clinical 
outcome is the age of diagnosis: children diagnosed before one year of age have 
better disease-free survival rates and less risk of recurrence (Schleiermacher et 
al., 2014).  
Malignant transformation of neuroblastoma cells is caused by gene 
mutations that affect signalling pathways involved in the development of the neural 
crest, both in familial (2 % of all cases) and sporadic neuroblastoma. PHOX2B, 
ATRX, TrkA and caspase 8, among others, are commonly mutated in 
neuroblastoma tissue or neuroblastoma cell lines. Allelic deletions have been 
related to advanced disease stages: 30 % of sporadic neuroblastoma have 
deletions in chromosome 1p, and 40 % in chromosome 11q. However, the most 
common genetic alteration in sporadic neuroblastoma is the amplification of MYCN 
(usually 50-100 fold), which occurs in 25 % of primary neuroblastoma tumours. 
The MYCN gene encodes a transcription factor that promotes proliferation, growth 
and survival of cells in the developing central nervous system. MYCN amplification 
is associated with advanced stages of the disease, rapid tumour progression and 
treatment failure (Davidoff, 2012; Kamijo and Nakagawara, 2012). Protein kinases 
are key in cellular signalling, and cell survival pathways altered in neuroblastoma 
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are not an exception. In fact, overexpression or hyperactivation of Akt, ALK or FAK 
protein kinases causes deregulation of cell growth, proliferation and survival and is 
common in neuroblastoma. Inhibitors for these kinases are being tested in phase 
I/II clinical trials (Megison et al., 2013). 
1.2 Src in neuroblastoma differentiation 
One of the most frequently used treatments for neuroblastoma is 
differentiation therapy. Neuroblastoma differentiation is driven by retinoids in vitro, 
and 13-cis-retinoid acid has become standard care for high-risk neuroblastoma. 
Although the mechanism by which retinoic acid induces differentiation is not 
understood, ERK and PI3K/Akt pathways are known to be required (Qiao et al., 
2012), as well as an increase in the cyclin-dependent kinase inhibitor (CDKI) 
protein p27 (Niles, 2004). Differentiation therapies are not directed to 
neuroblastoma with a specific genomic background and can therefore be applied 
to any subtype of tumour (Cheung and Dyer, 2013).  
The process of neuroblastoma differentiation has been studied by analysing 
both neuroblastoma tumours from patients with different prognosis and 
established neuroblastoma cell lines. A study by Mellström and Bjelfman (1987) 
used neuroblastoma cell lines defined to be in different stages of differentiation 
according to their neuron-specific enolase expression, to study changes during the 
differentiation process. The extent of neuronal enolase expression was shown to 
correlate with the activity of the tyrosine kinase Src, implicating Src in the 
differentiation of neuroblastoma cells. Interestingly, Src kinase activity levels and 
the malignant properties of neuroblastoma cell lines were inversely related. For 
example, SK-N-MC cells have a low Src activity but have the karyotype of highly 
malignant neuroblastoma, whereas SH-SY6Y cells have a high Src activity level 
and an almost normal karyotype. This contradicts the well-known oncogenic 
properties of Src (described in section 1.3.2) and suggests its involvement in 
neuroblastoma differentiation rather than proliferation. 
The link between Src and neural differentiation had been previously 
demonstrated in carcinoma cells that were treated with retinoic acid. There was an 
8 to 20-fold increase in the expression of Src when the cells started to grow 
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neurite-like processes and express neuronal markers (Lynch et al., 1986). The 
authors of this study described a decreased electrophoretic mobility of Src during 
this process, which corresponds to neuronal isoforms of Src. There are three 
splice variants of Src in the nervous system: C-Src, N1-Src and N2-Src. C-Src is 
ubiquitous, whereas N1-Src and N2-Src are neuronal-specific isoforms that 
contain insertions in the N-terminus of the protein (see section 1.4) Similarly, in 
vitro differentiation of neuroblastoma cells is concomitant with an increase in the 
amount (Horii et al., 1989) and activation (Bjelfman et al., 1990) of Src. Overall, 
these studies point to a role of Src, and specifically of N1-Src and N2-Src, in the 
neuroblastoma differentiation process. This was confirmed by Matsunaga et al. 
(1993, 1991) who analysed expression of Src in neuroblastoma from patients and 
found it to be increased in neuroblastoma with good prognosis or that had been 
differentiated by chemotherapy, but not in most of the tumours from patients over 
one year of age with a bad prognosis (Matsunaga et al., 1991). Another study 
showed a significant increase in N2-Src in samples from infantile neuroblastoma 
and little or no increase in neuroblastoma from patients older than one year. The 
levels of C-Src and N1-Src were similar among samples (Matsunaga et al., 1993). 
In vitro differentiation of neuroblastoma cell lines allowed the observation of 
changes in the expression of Src variants: while C-Src and N1-Src reached their 
maximum expression level at the beginning of the differentiation process, N2-Src 
increased its expression in later stages, suggesting that they have different roles 
(Matsunaga et al., 1993). 
Understanding the role of N2-Src in neuroblastoma differentiation could not 
only provide a prognosis marker (Matsunaga and Shirasawa, 1998), but also give 
insight into novel differentiation treatments. 
1.3 C-Src  
C-Src (sometimes referred to as pp60c-src) is a non-receptor tyrosine kinase, 
conserved in all metazoans, involved in the initiation of signal transduction 
pathways that lead to cell differentiation, proliferation, and survival (Frame, 2002). 
The C-Src homologue in Rous sarcoma virus, V-Src, is encoded by the first 
oncogene to be discovered and induces avian tumour formation (Martin, 2001; 
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Rous, 1911). C-Src is a member of the Src family kinases (SFKs), which includes 
ten other kinases in mammals: Blk, Brk, Fgr, Frk, Fyn, Hck, Lck, Lyn, Srm and 
Yes. Src, Fyn and Yes are ubiquitously expressed in all cell types, with particularly 
high levels in hematopoietic and neuronal cells (Parsons and Parsons, 2004), and 
often present redundant functions (Lowell and Soriano, 1996).  
1.3.1 Src structure and regulation 
Human Src is a 536 amino acid protein with a molecular weight of around 
60 kDa. SFKs share a common structure (Engen et al., 2008; Roskoski, 2004) 
comprising the following domains (from the N-terminus): SH4, unique, SH3, SH2, 
kinase and C-terminal regulatory region (Figure 1). The amino-terminal methionine 
is removed after protein synthesis and the SH4 domain is subsequently 
myristoylated in the resulting amino-terminal glycine. The myristate and a motif of 
three alternating lysines in the SH4 domain allow binding of Src to cellular 
membranes (Resh, 1994). The unique domain varies between SFKs, although it is 
conserved in each of the family members between different organisms. It is an 
intrinsically disordered region, at least in the absence of binding partners, and has 
been shown to interact with acidic lipids, the SH3 domain (Pérez et al., 2013) or 
other proteins (Gingrich et al., 2004). In addition, the unique domain contains 
target phosphorylation sites for several kinases involved in Src regulation and lipid 
binding (Amata et al., 2014; Pérez et al., 2009). 
 
Figure 1. Src domain structure. The ~60 kDa Src protein comprises a myristoylated SH4 domain, a unique 
domain, an SH3 domain, an SH2 domain, the catalytic domain and a C-terminal tail. Y416 and Y527 are 
important residues in Src regulation. 
The SH3 domain recognises left-handed helical structures, which are 
usually proline-rich sequences. The optimal SH3 ligands contain either the 
RPLPPLP (Class I) or the ΦPPLPXR motif (Φ represents a hydrophobic residue; 
Class II; Saksela and Permi, 2012). The SH3 domain is composed of five 
antiparallel β-strands and two prominent loops (RT and n-Src loops) that directly 
bind the target sequence (Boggon and Eck, 2004). Modifications in the n-Src loop 
cause changes in SH3 binding of neuronal isoforms of Src (see section 1.4). The 
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SH2 domain that follows the SH3 binds motifs containing a phosphorylated 
tyrosine, for which the consensus is pYEEI in the case of Src. SH3 and SH2 
domains have several important functions: first, they bind potential substrates; 
second, they allow the binding of proteins that attract Src to a specific localization 
(e.g., translocation to the plasma membrane); and third, they establish 
intramolecular interactions that are important for regulating the catalytic activity of 
Src (Roskoski, 2004). Finally, the Src tyrosine kinase domain has the bi-lobal fold 
that is characteristic of Tyr and Ser/Thr kinases. Phosphorylation of Y416 (chicken 
C-Src numbering is used) in the activation loop (C-terminal lobe) confers full 
catalytic activity to Src and allows the phosphotransfer reaction to occur in the cleft 
between the two lobes (Knighton et al., 1991). 
Regulation of Src activity (Roskoski, 2015; Xu et al., 1999) relies to a large 
extent on the phosphorylation of Y527 in the C-terminal tail. Y527 can be 
phosphorylated by Src-specific kinase (Csk) or Csk homologous kinase (Chk). 
Phosphorylated Y527 binds to the SH2 domain, thus favouring an inactive 
conformation (Figure 2). In this inactive conformation, the SH3 domain binds to the 
linker between the SH2 and the kinase domains, so that neither the SH2 nor the 
SH3 domains are available for the binding of external ligands. These interactions 
cause an α-helix in the kinase domain to swing outward into a conformation that 
impedes catalytic activity. Dephosphorylation of Y527 or the binding of SH2 and 
SH3 ligands induces disassembly of the intramolecular interactions. The α-helix is 
reoriented in the active form, causing the activation loop to adopt a conformation 
that is compatible with ATP and substrate binding. In addition, Y416 is exposed for 
subsequent autophosphorylation that allows full kinase activity. Whether SFKs act 
as on-off switches or if they can adopt different activation states depending on the 
activating inputs is not clear (Engen et al., 2008). In fact, the SH3-linker interaction 
has been demonstrated to act as an independent mechanism from the 
phosphorylation of the activation loop (Moroco et al., 2014). The intramolecular 
interactions of the inactive state have an entropic advantage for being in the same 
molecule, but are of relatively low affinity. Thus, only proteins with a high affinity 
for the SH2 and SH3 domains compete and release them, ensuring specificity 
(Boggon and Eck, 2004; Roskoski, 2004; Zvier et al., 1996). 
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Figure 2. Inactive and active conformations of Src. The inactive conformation of Src is maintained by 
intramolecular interactions between phosphorylated Y527 and the SH2 domain, and between the SH3 domain 
and the SH2-kinase domain linker. When Y527 is displaced by a Src activator, the kinase domain is no longer 
locked. In this conformation, Y416 can be phosphorylated and the enzyme is active. 
1.3.2 C-Src function 
SFKs mediate signal transduction in many different pathways involved in 
cell survival, growth, proliferation, cell shape, migration and other specialised 
signals. They can be activated by a variety of plasma membrane receptors, such 
as growth factor receptors (EGFR, PDGF, IGF and FGF families), cytokine 
receptors, G-protein coupled receptors, voltage or ligand-gated channels, major 
histocompatibility receptors, E-cadherin and integrin receptors (Parsons and 
Parsons, 2004). It is not surprising that mutations, deregulation or changes in 
intracellular localization of C-Src promote cancer development and a constitutively 
active form of C-Src is found in epithelial human cancers (Frame, 2002). The 
possible function of C-Src in neuronal differentiation (see sections 1.2 and 1.4.1) 
contrasts with its oncogenic properties that stimulate growth and migration in 
cancerous cells. 
Specific roles for Src have been found in the central nervous system. Src is 
thought to have an important role in neuron development, most likely undertaken 
by its neuronal isoforms, which will be discussed in section 1.4.1. C-Src’s roles in 
differentiated neurons include regulation of synaptic transmission and plasticity 
(Kalia et al., 2004) by, for instance, upregulating the function of NMDA (N-methyl-
D-aspartate receptor) receptors (Wang and Salter, 1994). In addition, C-Src has 
?
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been implicated in membrane trafficking in neurons (Evans and Cousin, 2007; 
Foster-Barber and Bishop, 1998; Messina et al., 2003) and in neuronal migration 
(Wang et al., 2015). 
The majority of C-Src is located in a perinuclear region. It has been 
described to localize with the nuclear envelope and juxtanuclear reticular 
membrane structures (Krueger et al., 1980), the Golgi apparatus (Bard et al., 
2002) and endosomes in the trans-Golgi region of fibroblasts (Kaplan et al., 1992). 
Upon activation, C-Src migrates to focal adhesions, lamellipodia or filopodia in a 
process dependent on the small GTPases Rho, Rac and Cdc42, respectively 
(Sandilands and Frame, 2008). Sandilands et al. (2004) demonstrated that there is 
a gradient of C-Src activity between the perinuclear region and peripheral 
membrane structures after growth factor stimulation: C-Src is mostly inactive in the 
perinuclear region, whereas it is mostly active in the plasma membrane. 
Translocation occurs in RhoB-containing endosomes and is dependent on actin 
polymerization. C-Src kinase activity (Timpson et al., 2001) and the SH3 domain 
(Fincham et al., 2000) are necessary. Once at the plasma membrane, activated C-
Src in the cell periphery binds the plasma membrane and the actin cytoskeleton 
through SH4 domain lipid modifications (Resh, 1994) and can interact with 
receptors to induce signalling pathways. 
1.4 Neuronal Srcs 
There are three Src splice variants in the nervous system: the ubiquitous C-
Src, N1-Src, and N2-Src (Figure 3). Interest in neuronal Src was raised when Src 
expression was found to be 8 to 10 fold higher in neural tissues than in others in 
chicken (Cotton and Brugge, 1983). In particular, high Src expression occurred in 
neuronal cells but not in other nervous system cell, such as CNS astrocytes in rat 
(Brugge et al., 1985). Brugge et al. (1985) described for the first time a neuronal 
form of Src that had a reduced electrophoretic mobility. The shift in electrophoretic 
mobility was not due to different posttranslational modifications, but to the 
formation of a distinct product by alternative splicing of Src mRNA (Brugge et al., 
1987; Levy and Dorai, 1987) that could be isolated from human brain tissue (Pyper 
and Bolen, 1989). This form of Src, N1-Src, includes 6 extra amino acids (Arg-Lys-
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Val-Asp-Val-Arg) as a result of an 18 nucleotide insertion (microexon NI) between 
exons 3 and 4 (Figure 3). In addition to NI, a novel neuronal Src microexon (NII) 
was found to be expressed in human brain (Pyper and Bolen, 1990). NII 
comprises 33 nucleotides that encode 11 amino acids (Gln-Thr-Trp-Phe-Trp-Phe-
Arg-Trp-Leu-Gln-Arg; Figure 3B). NII is only expressed in conjuction with NI, 
resulting in a 17 amino acid insert. When this occurs, the last amino acid of NI 
exon changes from Arg to Ser (Figure 3B; Pyper and Bolen, 1990). Although C-
Src is found in all metazoans, N-Srcs have a more recent origin, with N1-Src 
arising in low vertebrates (teleost fish; Raulf et al., 1989) and N2-Src only found in 
mammals. 
 
Figure 3. Splice variants of Src. (A) Fragment of Src pre-mRNA that shows exon 3 to exon 4, including 
microexons NI and NII. Inclusion of NI and NII microexons during mRNA splicing results in the formation of 
N1-Src and N2-Src, respectively. (B) Fragments of the amino acid sequences of C-Src, N1-Src and N2-Src 
SH3 domains. Amino acids corresponding to the NI microexon are found in N1-Src, and to both NI and NII 
microexons in N2-Src. 
The mechanism of Src alternative splicing has mainly been studied for the 
NI micrexon. A number of positive and negative regulatory regions between exons 
3 and 4 control NI microexon expression spatially (tissue-specific) and temporally 
(during development; Black, 2003). There is a region termed the Downstream 
Control Sequence (DCS), located in the intron downstream of NI, that is important 
for regulation of splicing. It contains repeats to which polypyrimidine tract binding 
protein (PTB) binds, resulting in NI splicing repression. In neuronal cells, PTB is 
removed to derepress NI splicing (Black, 1992, 1991). KH-type splicing regulatory 
protein (KSRP) binds to activating sequences in the DCS and recruits other 
proteins to form the DCS complex, which is necessary for the inclusion of the 
microexon in neuronal cells (Modafferi and Black, 1999). The inclusion of NI rises 
during neuroblastoma cell differentiation, which agrees with the fact that KSRP 
?????
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increases its association with Src mRNA during N1E neuroblastoma cells 
differentiation induced with DMSO (Hall et al., 2004). Additional control sequences 
upstream and inside the microexon contribute to the tight and complex regulation 
of NI splicing. 
The inclusion of NI and NII microexons has important consequences for the 
structure and thus the function and regulation of C-Src. N-Src’s additional amino 
acids are inserted in the n-src loop of the SH3 domain, changing its interaction 
interface. By comparing two V-Src forms with different basal kinase activities in 
vitro, it was found that residues in the n-src loop of the SH3 domain are 
responsible for determining activity in V-Src (Brábek et al., 2002). Similarly, 
additional amino acids in the n-src loop in N-Srcs endows them with 5 to 7 times 
higher intrinsic kinase activity compared to C-Src (Brugge et al., 1985; Inomata et 
al., 1994). This was extensively studied by Keenan et al. (2015). In vitro, N-Src 
autophosphorylation of Y416 was shown to be higher than for C-Src and was four 
times higher in N2-Src than N1-Src. Y416 phosphorylation was also shown to be 
higher in comparison to C-Src in cells, whereas the levels of phosphorylated Y527 
were similar for C-Src and N1-Src but a lot lower for N2-Src (Keenan et al., 2015). 
Also, tyrosine phosphorylated proteins were more abundant in N2-Src 
overexpressing cells than in C-Src and even N1-Src overexpressing cells (Keenan 
et al., 2015). The high intrinsic kinase activity of N-Srcs could be explained by a 
lower affinity of the SH3 domain for the SH2-kinase linker, which would lead to an 
open conformation. Indeed, there was a reduction in the Km of the phosphorylation 
of a C-Src ideal substrate that was fused to the linker sequence by the N-Srcs 
when compared to the Km of C-Src (Keenan et al., 2015). The reduction was more 
pronounced in the case of N2-Src (Keenan et al., 2015). These differences could 
be explained by the steric hindrance of the additional amino acids in the n-src loop 
or by their charge (Dergai et al., 2010). 
Apart from a lower affinity for the SH2-kinase linker, the SH3 domain of N-
Srcs has a different affinity for peptides, which leads to a distinct substrate 
specificity. Phosphorylation of an ideal substrate is enhanced by the presence of a 
C-Src ligand in the case of C-Src, but not in the case of N1-Src or N2-Src (Keenan 
et al., 2015), which means that the proline-rich sequences that are preferentially 
bound by N2-Src might be different to those of C-Src. Indeed, a number of 
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different proteins bind to C-Src but not to N-Srcs, including 3BP-1 (Cicchetti et al., 
1992), Sam68 (Finan et al., 1996), dynamin 1 and synapsin (Dergai et al., 2010; 
Foster-Barber and Bishop, 1998), FAK (Messina et al., 2003), the microtubule-
associated protein tau (Reynolds et al., 2008) and synaptophysin (Keenan et al., 
2015). In fact, the N1-Src SH3 domains only interact with a subset of the proteins 
that interact with the C-Src SH3 domain (Weng et al., 1993). Therefore, N-Srcs are 
not simply constitutively activated forms of C-Src, but kinases with a distinct 
specificity. A few proteins have been described to interact with the N1-Src SH3 
domain in vitro: delphilin (Miyagi et al., 2002), the formin DAAM1 (Aspenström et 
al., 2006), NMDA receptor NR2A subunit (Groveman et al., 2011), the subfamily of 
K+ channels BCNG-1 (Santoro et al., 1997) and the focal adhesion-localized EVL 
(Enah/VASP-like protein; Lambrechts et al., 2000). BCNG-1 and EVL, in particular, 
show a strong affinity for N-Srcs but a very low affinity for C-Src.  
The SH4 domain is not thought to be altered by the insertion of NI and NII 
microexons, and N-Srcs could therefore be myristoylated to allow binding to 
membranes as in the case of C-Src. 
1.4.1 N-Src function 
Whereas many roles have been described for C-Src in the nervous system, 
little is known about the functions of N1-Src and N2-Src. N1-Src has often been 
linked with neuronal differentiation during development. Immunocytochemistry 
analysis shows N1-Src localization in neurite processes and growth cones 
(Maness and Aubry, 1988; Sugrue et al., 1990) and high expression of N1-Src is 
concomitant with neurogenesis and neuronal growth during early stages of 
development (Cartwright et al., 1988; Fults and Towle, 1985). Indeed, 
overexpression of N1-Src induces the growth of neurite-like processes in Xenopus 
epithelial cells (Worley et al., 1997). Another study related N1-Src function to the 
acquisition of neuronal morphology in Purkinje cells, as N1-Src but not C-Src 
overexpression caused deformities in microtubules and disrupted dendrite 
morphogenesis (Kotani et al., 2007). The only N-Src interaction that has been 
shown to occur in cells is that of N1-Src with the NMDA receptor. Interestingly, 
expression of a constitutively active form of N1-Src (Y527F) increased NMDA 
receptor-mediated whole-cell currents in HEK-293 cells in a kinase independent 
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but SH2 and SH3 domain-dependent manner (Groveman et al., 2011). Finally, the 
N1-Src homologue in Xenopus tropicalis was demonstrated to be necessary for 
correct primary neurogenesis, indicating that N-Srcs have a role in normal neural 
development (Lewis, 2014). Unfortunately, no interactors have been described for 
N2-Src. 
The recent emergence of N2-Src in evolution suggests a role in higher 
functions of the nervous system in mammals, but neuroblastoma differentiation is 
the only process in which this Src variant has been implicated to date. A set of 
unpublished experiments previously performed in our laboratory showed that the 
N-Srcs, as opposed to C-Src, were able to induce the growth of neurite-like 
processes in the neuroblastoma cell line KELLY and to reduce the expression of a 
proliferation marker in another neuroblastoma cell line, SK-N-AS (Lewis, 2014). In 
both cases, the results were more pronounced with N2-Src overexpression. These 
observations clearly relate N2-Src to neuroblastoma differentiation and are 
consistent with those reported by Matsunaga et al. (1993). 
1.5 Potential substrates of N2-Src: the COPII complex 
In order to elucidate the role of N2-Src in neuroblastoma differentiation, it is 
important to understand its downstream signalling. Preliminary phosphoproteomic 
analyses have been performed in our laboratory in an effort to identify potential 
N2-Src substrates (Lewis, 2014). HeLa cell lines that inducibly expressed C-Src-
FLAG or N2-Src-FLAG upon addition of doxycycline were used to compare 
tyrosine phosphorylation induced by each of these kinases. A phosphotyrosine IP 
(pY-IP) was performed from C-Src or N2-Src overexpressing cells lysates and 
immunoprecipitated proteins were analysed by mass spectrometry. The 
abundance of a specific protein in the IPs was then calculated (Lewis, 2014).  
The proteins that were significantly enriched in the pY-IP from N2-Src 
overexpressing cells compared to C-Src overexpressing cells were clustered 
based on ontology terms using bioinformatic software (Lewis, 2014). Proteins 
related to the following cell functions were recovered: mRNA processing and 
translation (spliceosome and ribosome proteins), membrane traffic (endocytosis, 
COPII coat), cytoskeleton regulation (WAVE2 complex), and cell-cell junctions 
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(Figure 4A; Lewis, 2014). These protein clusters potentially contain N2-Src 
substrates and could be targets of signalling downstream of N2-Src (Lewis, 2014). 
 
Figure 4. COPII proteins enrichment in a pY-IP from N2-Src overexpressing cells compared to C-Src 
overexpressing cells. A pY-IP was performed from C-Src or N2-Src overexpressing cells lysates, and 
immunoprecipitated proteins were analysed by mass spectrometry. (A) Proteins that were enriched in the pY-
IP from N2-Src overexpressing cells when compared to C-Src overexpressing cells were identified. This 
diagram shows enriched proteins grouped according to their function and interactions. (B) Graph showing 
COPII proteins abundance (%emPAI) from mass spectrometry data from C-Src and N2-Src overexpressing 
cells pY-IPs. (C) Map showing the interactions between the COPII proteins found to be highly enriched in the 
N2-Src overexpressing cells pY-IP. From Lewis (2014). 
Components of the COPII complex (Sec16A, Sec23A, Sec23B, Sec24A, 
Sec24B and Sec24C) were highly enriched in the N2-Src pY-IP (Figure 4B) and 
had very few interactions with other immunoprecipitated proteins (Figure 4C; 
Lewis, 2014), which suggests that at least one of these proteins is a substrate of 
N2-Src. It is possible that only one of them is an N2-Src substrate, which has co-
purified the remaining complex components. Unfortunately, no tyrosine 
phosphopeptides from COPII proteins were recovered and thus a particular 
protein/residue could not be identified. 
1.5.1 COPII complex structure and function 
The coat protein II (COPII) complex is responsible for vesicle trafficking 
from the endoplasmic reticulum (ER) to the Golgi apparatus (Figure 5A). COP 
vesicles were first described by Orci et al. (1986) as non-clathrin buds located next 
to the Golgi stacks. Later, COPII vesicles were named so as to differentiate them 
from COPI vesicles that migrated from the Golgi apparatus to the ER (Barlowe et 
al., 1994). The genes encoding the COPII proteins were known from studies by 
Randy Schekman on the secretory machinery in yeast (Rexach et al., 1992). 
Today we know that COPII vesicles travel in animal cells from the ER to the ER-
Golgi intermediate compartment (ERGIC) in a first step to transport cargo proteins 
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and lipids to the Golgi apparatus and towards the plasma membrane, the 
secretory pathway or the degradation pathway (van Vliet et al., 2003).  
COPII-coated vesicles form at the endoplasmic reticulum exit sites (ERES; 
Figure 5B), which form de novo but also undergo fusion and fission events. They 
are located at ER tubules or at the edge of ER sheets and tend to accumulate in 
the perinuclear region (Kirk and Ward, 2007; Stephens, 2003). The formation of 
COPII vesicles (D’Arcangelo et al., 2013) starts with the recruitment of the small 
GTPase Sar1 by its GEF Sec12 (Figure 5B). GTP-Sar1 inserts its N-terminal 
region in the plasma membrane, promoting its bending (Lee et al., 2005). GTP-
Sar1 then interacts with cytoplasmic Sec23 and recruits the Sec23/Sec24 
heterodimer, which will form the inner COPII coat layer (Figure 5B). Sec23 and 
Sec24 are highly related proteins in their primary sequence and 3D structure that 
form a concave heterodimer (Bi et al., 2002) that exposes basic residues on its 
inner face, facilitating acid phospholipid binding in the ER membrane (Matsuoka et 
al., 1998). Sec23/Sec24 is responsible for cargo recognition and binding from the 
ER lumen, directly or through adaptor proteins (Kuehn et al., 1998). One of the 
mechanisms for cargo discrimination is, in fact, the presence of different 
packaging signals in the four Sec24 isoforms expressed in mammalian cells 
(Mancias and Goldberg, 2008). GTP-Sar1 is also thought to link cargo sorting to 
COPII assembly/disassembly (Aridor et al., 1998; Kuehn et al., 1998). 
The outer layer of the coat is formed upon binding of the Sec13/Sec31 
heterotetramer to Sec23 (Lederkremer et al., 2001; Figure 5B). Sec13/Sec31 
heterotetramers enhance membrane curvature and determine the 
cubohectahedral shape of the cage (Fath et al., 2007), which allows the transport 
of cargoes of different sizes due to its characteristic flexibility (Stagg et al., 2008). 
Sar1 GTP hydrolysis, prompted by Sec23 (GAP) and Sec31, then drives the 
complete budding of the vesicle (Figure 5B). Sec23 inserts an arginine finger into 
the active site of Sar1, stabilising the transition state for GTP hydrolysis. 
Presumably, Sec31 is required for an effective Sec23 GAP activity, which explains 
why the coat does not disassemble until it is complete (Antonny et al., 2001).  
Essential to the formation of COPII vesicles is the 250 kDa protein Sec16A 
(Figure 5B). Sec16A can interact with the other COPII proteins, working as a 
scaffold by tethering all components to form ERES (Connerly et al., 2005; Watson 
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et al., 2006) and even regulating the localization of COPII vesicle formation 
upstream of Sec12 (Yorimitsu and Sato, 2012). However, these roles have been 
refuted by Bharucha et al. (2013). Regardless, Sec16A has an important role in 
counteracting the intrinsic tendency of the coat to disassemble by inhibiting Sar1 
GTPase activity in a Sec24 dependent manner and negatively regulating Sec31 
GAP activity over Sar1 (Yorimitsu and Sato, 2012). It therefore prevents the 
disassembling of the coat before the vesicle is completed. There is a smaller 
isoform, Sec16B, that has non-redundant roles with Sec16A and is thought to be a 
specialised form of the protein (Budnik et al., 2011). 
 
Figure 5. COPII vesicles trafficking and formation. (A) Trafficking between the ER and the Golgi apparatus 
is directed by COPI and COPII-coated vesicles. (B) The formation of COPII-coated vesicles in the ER 
membrane starts with Sar1 GDP-GTP exchange promoted by Sec12. GTP-Sar1 recruits Sec23/Sec24 (inner 
coat layer), which in turn recruits Sec13/31 (outer coat layer). Sar1 GTP hydrolysis allows vesicle budding. 
Sec16’s scaffolding role is shown (adapted in part from D’Arcangelo et al. (2013). 
After budding, COPII-coated vesicles are transported by dynein via 
microtubules to the ERGIC in mammalian cells. Sec23 interacts with dynactin, a 
protein essential to dynein function (Watson et al., 2005). However, there is some 
controversy in this matter and different models have been proposed: in yeast, cis-
Golgi approaches the ERES and captures cargo right after vesicle is released and 
collapsed (Kurokawa et al., 2014); in mammalian cells, oligomers of protein TFG 
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maintain ER and ERGIC in tight association and cluster COPII components at that 
interface (Johnson et al., 2015). COPII proteins are involved in vesicle tethering to 
the target membrane before been recycled back to the ERES: Sec23 interacts with 
tethering proteins such as TRAPPI (Cai et al., 2007) and the yeast orthologue of 
GRASP65 (Behnia et al., 2007). 
1.5.2 Post-translational modifications of COPII complex components 
Numerous factors modulate the COPII cycle, including cytosolic proteins 
and cargoes themselves (D’Arcangelo et al., 2013; Lee and Miller, 2007; Venditti 
et al., 2014). Post-translational modifications, of which phosphorylation is the most 
common, are key to the regulation of many cell processes, and ER-Golgi traffic is 
no exception (Table 1). COPII complex regulation has mostly been studied in the 
context of the cell cycle (Farmaki et al., 1999; Prescott et al., 2001). p38 MAPK is 
known to phosphorylate the Sec13/Sec31 dimer, inhibiting its loading into ERES in 
HeLa cells (Wang and Lucocq, 2007). Other MAPK pathway proteins 
phosphorylate Sec16: ERK2 (Farhan et al., 2010) and ERK7, whose 
overexpression induces Sec16 cytoplasmic dispersion and restrains protein 
secretion in Drosophila and human cells (Zacharogianni et al., 2011). The 
Parkinson’s disease-related protein LRRK2, on the contrary, phosphorylates 
Sec16 and is required for its localization to ERES in Drosophila (Cho et al., 2014). 
Akt has been shown to phosphorylate Sec24 and thus increase Sec23 binding 
affinity (Sharpe et al., 2011), and CK2 to target Sec31 (Koreishi et al., 2013). 
Interestingly, coat phosphorylation and dephosphorylation are essential for the 
fusion and budding of the vesicle, respectively. Indeed, Golgi resident protein 
Hrr25p (CK1δ ortholog in yeast) phosphorylates Sec23/Sec24 (Lord et al., 2011), 
whereas the phosphatase Sit4p (PP6 ortholog) dephosphorylates Sec31 
(Bhandari et al., 2013), providing vesicle transport with directionality. 
Other types of post-translational modification have also been detected in 
COPII proteins (Table 1). Ubiquitination of Sec31 by CUL3-KLH12 induces the 
formation of large vesicles that are able to accommodate procollagen fibers (Jin et 
al., 2012). Ubp3/Brc5 deubiquitinates Sec23 in S. cerevisie, preventing its 
proteosomal degradation and modulating COPII transport (Cohen et al., 2003). 
Also, the addition of O-GlcNAc to Sec24 increases its binding to cellular 
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membranes and favours COPII traffic during cell interphase (Dudognon et al., 
2004). 
1.5.3 The COPII complex in neuronal differentiation  
The function of the COPII complex is an essential housekeeping function in 
all cell types. In addition, the subtle control of its function allows many specific 
cellular processes, including cellular differentiation. The COPII complex is 
implicated in the inhibition of cell proliferation and growth (Table 1). This is 
exemplified in cancerous cells in which the downregulation of Sec23A by miRNAs 
promotes tumour growth and metastasis. Sec23A promotes the secretion of 
factors that suppress metastasis and stimulate mesenchymal-epithelial transition 
(MET) in breast cancer cells, a function that is inhibited by the poor prognosis-
related miRNA-200 (Korpal et al., 2011). Sec23 expression was higher in breast 
cancer primary tumours than in metastasis samples, consistent with the idea that 
Sec23 is a suppressor of metastasis (Korpal et al., 2011). Similarly, miRNA-375 is 
found to downregulate Sec23A in prostate carcinoma, in which Sec23 
overexpression leads to a decrease in cell growth (Szczyrba et al., 2011). 
Moreover, the function of COPII components is specifically important in 
neuronal differentiation (Table 1). Growth and branching of neurites and dendrites 
during morphological changes in neuronal differentiation require large amounts of 
additional plasma membrane (Bradke and Dotti, 1997). The transport of specific 
sets of proteins and lipids from the ER to the periphery of the cell must occur in 
order to create a polarized neuronal cell. Indeed, blocking secretory vesicle export 
impedes cell morphological changes (Horton et al., 2005; Lecuit and Pilot, 2003). 
Interestingly, ER to Golgi transport is more important for dendritic than for axonal 
growth in rodent and Drosophila neurons, as shown in Sar1 defective cells (Ye et 
al., 2007). The secretory pathway has been linked to dendrite development in 
Drosophila melanogaster, as Sar1, Sec13, Sec31, Sec23 and Sec24 are up-
regulated by the transcription factor Cut via CrebA to promote dendrite 
morphogenesis in sensory neurons (Iyer et al., 2013). Sec31 causes an increase 
in dendritic branching density and growth in class I neurons (Iyer et al., 2013). It 
also increases the number of satellite ER and Golgi outposts in dendrites, known 
to be required for branch dynamics (Ye et al., 2007). According to another study in 
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hippocampal neurons, Sec16A recruits other COPII proteins and forms dendrite 
ERES upon phosphorylation by Parkinson disease-related protein LRRK2 (Cho et 
al., 2014). Dendrite ERES control the assembly and export of dendritic proteins, 
particularly NMDA receptors, and therefore are essential for neuronal 
differentiation (Jeyifous et al., 2009). Loss of Sec16A blocks NMDA receptor 
translocation to the cell surface (Cho et al., 2014). Lastly, Sec24 expression is 
necessary for axon targeting of the GABA transporter-1, a prototypical protein of 
the synaptic specialization (Reiterer et al., 2008). 
Table 1. Summary of the effect of COPII components post-translational modification overexpression 
or depletion on COPII traffic and cell differentiation.  
COPII component Type of regulation Effect on COPII traffic 
Effect on cell 
differentiation 
Sar1 siRNA knock-down Negative Negative 
Sar1, Sec13, Sec31, 
Sec23, Sec24 
Transcriptional upregulation 
by CrebA Positive Positive 
Sec13/Sec31 dimer Phosphorylation by p38 Negative Not known 
Sec16 Phosphorylation by ERK7 Negative Not known 
Sec16 Phosphorylation by LRRK2 Positive Positive 
Sec16 siRNA knock-down Negative Negative 
Sec23/Sec24 dimer Phosphorylation by Hrrp25p Positive Not known 
Sec23A siRNA knock-down Negative Negative 
Sec24 Phosphorylation by Akt Positive Not known 
Sec24 O-Glycosylation Positive Not known 
Sec24 siRNA knock-down Negative Negative 
Sec31 Dephosphorylation by Sit4p Positive Not known 
Sec31 Deubiquitination by Ubp3/Brc5 Positive Not known 
Sec31 Protein overexpression Positive Positive 
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1.6 Hypothesis and project aims 
N2-Src is involved in neuronal differentiation and believed to induce 
differentiation of neuroblastoma cells. Dissecting the signalling downstream of N2-
Src would help to understand this mechanism, which could lead to novel 
differentiation therapies in neuroblastoma treatment. Our preliminary data 
identified the COPII complex as a potential substrate of N2-Src. COPII transport 
has been implicated in halting proliferation and growth and promoting neuronal 
differentiation. Therefore, the hypothesis of this project is that the COPII complex 
is involved in N2-Src mediated differentiation of neuroblastoma cells. 
To address our hypothesis, the overall objectives were:  
• To investigate the COPII complex as an interactor/substrate of N2-Src. 
• To investigate the role of the COPII complex in N2-Src induced differentiation 
of neuroblastoma cells.  
The methodological approaches taken to achieve these aims were varied. 
The interactions between N2-Src and the COPII complex were studied using a 
biochemical approach, which consisted of immunoprecipitation experiments 
performed on N2-Src overexpressing cells. A stable HeLa cell line that inducibly 
expressed FLAG-tagged N2-Src upon the addition of doxycycline was chosen as 
the model system for these experiments. Independently, immunocytochemistry 
experiments permitted analysis of the cellular localisation of N2-Src and COPII 
proteins in COS7 cells. N2-Src expression in COS7 cells promotes the extension 
of processes, providing a cell-based model for studying the effect of COPII protein 
overexpression on N2-Src induced neurite outgrowth. Finally, neuroblastoma SK-
N-AS cells were used as a more physiological model to study neuroblastoma 
differentiation. Sec23A was selected as the principal experimental target because 
it was the most abundant COPII protein in the phosphoproteomic analysis. Sec13 
was also studied, as it has been shown to be essential for COPII function 
(Townley et al., 2008) and served to study COPII complex function as a whole.  
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Chapter 2. Materials and methods 
2.1 Materials 
The following antibiotics were used: ampicillin (Melford), kanamycin (Sigma-
Aldrich), penicillin/Spreptomycin (Gibco), G418 disulfate (PanReac AppliChem), 
puromycin (Sigma-Aldrich), doxycycline hyclate (Santa Cruz Biotechnology), 
hygromycin B and penicillin/streptomycin (Invitrogen). Restriction enzymes ScaI 
and ClaI were purchased from Promega and Thermo Scientific, respectively. The 
SK-N-AS neuroblastoma cell line was a kind gift from Dr. Andrew Stoker, 
University College London. DMEM and RPMI mediums and FBS were from Gibco 
and trypsin/EDTA from Invitrogen. Lipofectamine 2000 was purchased from 
Invitrogen, and EcoTransfect from Ozbiosciences. Protease inhibitor cocktail was 
from Sigma-Aldrich. Miniprep kit (Nucleo Spin Plasmid, Qiagen) and midiprep kit 
(Machery-Nagel) were used. Laemmli buffer was from Sigma-Aldrich, Precision All 
Blue molecular weight markers were from Bio-Rad and SYBR Safe from Life 
Technologies. Autoradiography film was from Santa Cruz. 
Rabbit polyclonal α-Sec13 and α-FLAG, and mouse monoclonal anti-β-
actin antibodies were purchased from Proteintech. Mouse monoclonal α-HA was 
obtained from Thermo Scientific and rabbit polyclonal α-Sec23A antibody from 
GeneTex. α-rabbit IgG (whole molecule) and α-mouse IgG (whole molecule) 
peroxidase-conjugate secondary antibodies were purchased from Sigma-Aldrich. 
Agarose beads covalently attached to α-FLAG antibody (α-Flag M2 Affinity Gel) 
were from Sigma-Aldrich, agarose beads covalently attached to α-
phosphotyrosine antibody (clone 4G10; from Merck Millipore) and protein G 
agarose resin were obtained from GenScript. Immobilon Chemiluminescent HRP 
Substrate was from Merck Millipore. 
All other chemicals were purchased from Sigma-Aldrich. 
2.2 Plasmids 
The source and composition of the plasmids used for protein expression in 
mammalian cells are stated in Table 2. The HA-Sec13 (Addgene plasmid 46332) 
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and GFP-RhoB (Addgene plasmid 23225) plasmids were gifts from David Sabatini 
(Bar-Peled et al., 2013) and Channing Der (Roberts et al., 2008), respectively. The 
vector FLAG-N1 for the cloning of FLAG-C-Src and FLAG-N2-Src was created by 
substituting the EGFP gene in pEGFP-N1 (Clontech) with a FLAG tag (Keenan et 
al., 2015). Sarah Wetherill created pmCherry-N1 for the cloning of Cherry-C-Src 
and Cherry-N2-Src by substituting the EGFP gene in the pEGFP-N1 vector 
(Clontech) with mCherry. FLAG and Cherry tags were inserted at the C-terminus 
of Src, separated by a glycine/serine-rich flexible peptide linker (Keenan et al., 
2015). Sandilands et al. (2004) tested a similar C-Src-GFP construct that 
contained the linker and confirmed that the activity, regulation and substrate 
binding were the same as wild-type C-Src’s. 
Table 2. Composition and source of plasmids used for protein expression in mammalian cells. 
2.3 Culture of mammalian cells 
Cells were maintained at 37 ºC in a humidified atmosphere with 5 % CO2, in 
25 cm2 or 75 cm2 flasks. HeLa, COS7 and SK-N-AS cells were cultured in DMEM 
supplemented with D-glucose, L-glutamine and pyruvate with 10 % FBS and 1 % 
penicillin/steptromycin. N2‑Src-FLAG HeLa cells were cultured in 50 µg/ml 
hygromycin B to select cells that contained the plasmid of interest. Cells were 
passaged two or three times a week as follows: the culture medium was removed, 
cells were washed with PBS and 1x trypsin/EDTA in PBS was added to cover the 
cell layer for 3 to 5 min. Trypsin was neutralized with 5 or 10 ml of culture medium 
and centrifuged at 130 g for 5 min. The cell pellet was resuspended in culture 
Gene of interest Species Tag (terminus) Vector Source 
C-Src Rat FLAG (C) pFLAG-N1 Dr. Gareth Evans 
C-Src Rat Cherry (C) pCherry-N1 Dr. Gareth Evans 
N2-Src Rat FLAG (C) pFLAG-N1 Dr. Gareth Evans 
N2-Src Rat Cherry (C) pCherry-N1 Dr. Gareth Evans 
RhoB Rat GFP (N) pEGFP-C2 Dr. Channing Der 
Sec13 Human HA (N) pRK5 Dr. David Sabatini 
Sec23A Human HA (N) pFLAG-N1 Dr. Gareth Evans 
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medium and split into flasks for passaging or quantified in a haemocytometer 
(Hawksley) for subsequent plating. 
2.4 Plasmid amplification and purification 
2.4.1 Preparation of competent cells 
E. coli initially purchased from Stratagene were grown in 5 ml sterile LB 
medium (1 % tryptone, 0.5 % yeast extract, 1 % NaCl in dH2O) overnight. A 1:100 
dilution of the overnight culture was diluted in 200 ml of LB supplemented with 4 
ml of 1 M MgSO4 and grown until O.D.600 = 0.6. Cells were then pelleted at 4,500 g 
for 5 min at 4 ºC, and resuspended in 50 ml of ice-cold TFB1 buffer (30 mM 
CH3CO2K, 10 mM CaCl2, 50 mM MnCl2, 0.1 M RbCl in dH2O pH 5.8 with 15 % 
glycerol). After 5 min incubation on ice, the cells were pelleted and resuspended in 
5 ml TFB2 buffer (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl in dH2O pH 6.5 with 
15 % glycerol). Cells were incubated for 1 h on ice and aliquoted. Finally, they 
were snap-frozen in a liquid N2 bath and stored at -80 ºC. 
2.4.2 Bacterial transformation 
50 µl of XL-10 Gold competent E. coli were transformed with 1 µg of 
plasmid DNA and incubated on ice for 15 to 30 min. They were then heat-shocked 
for 45 s at 42 ºC and incubated on ice for 2 min before adding 400 µl of LB 
medium (10 g tryptone, 10 g NaCl and 5 g yeast extract per litre) and incubated at 
37 ºC for 30-60 min with 200 rpm mixing. 100 µl of cultured bacteria were plated 
on agar plates (10 g tryptone, 10 g NaCl, 5 g yeast extract and 20 g agar per litre) 
containing 100 µg/ml ampicillin or 50 µg/ml kanamycin and incubated at 37 ºC 
overnight.  
2.4.3 Plasmid purification 
Single colonies were grown in selective LB medium at 37 ºC before lysis 
and plasmid purification using miniprep or midiprep kits, following the 
manufacturers’ instructions. Final DNA concentration was measured using a 
NanoDrop spectrophotometer (Technology Facility, University of York). 
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2.5 Transient transfection 
Cells were plated the day before transfection (the number of cells and 
volume of medium used for each type of experiment is specified in Table 1). 
Different lipid-based transfection systems were used depending on the type of 
experiment (Table 1): EcoTransfect or Lipofectamine 2000, following 
manufacturers’ instructions. Briefly, transfection protocols were as follows: DNA 
and transfection reagent were diluted in serum-free culture medium in different 
tubes (quantities specified in Table 1), then mixed and incubated for 20 min at 
room temperature to allow the formation of lipid-DNA complexes before addition to 
the cells. Fresh culture medium was added 6 h after transfection. When 
appropriate, 1 µg/ml doxycycline was included. Cells were fixed or lysed 48 h after 
transfection, except in the case of SK-N-AS cells, which were incubated 96 h after 
transfection.  
Table 3. Protocol details for transient transfections. Different transfection methods were used for 
immunocytochemistry (IC) and immunoprecipitation (IP) experiments. The type of culture dish that was used, 
the number of cells plated the day before transfection, the total volume of culture medium in which the cells 
were transfected, the type of transfection reagent used, and the quantity of DNA and reagent volume used per 
well/flask are specified for each type of experiment. 
2.6 Immunocytochemistry 
2.6.1 Cell fixation and staining 
Cells plated on 13 mm glass coverslips in 24 well plates were washed three 
times in 1 ml PBS and fixed in 0.5 ml paraformaldehyde (4 % paraformaldehyde, 4 
% sucrose in PBS, pH 7.4) for 20 min at room temperature. The cells were 
washed three times in 1 ml PBS before permeabilization and blocking in 200 µl 0.1 
% Triton X-100 and 1 % BSA in PBS for 30 min. The cells were incubated with the 
primary antibody at the specified dilution (Table 4) in 1 % BSA in PBS for 2 h at 
room temperature. After three washes in 1 ml PBS the cells were incubated with 
the secondary antibody in the specified dilution (Table 4) in 1 % BSA in PBS for 
 Culture dish Cell 
number 
Medium 
volume 
Transfection 
reagent 
DNA 
quantity 
Reagent 
volume 
IC  24 well plate  3·104 0.5 ml EcoTransfect 1 µg 2 µl 
IP 75 cm2 flask 1.5·106 12 ml Lipofectamine 15 µg 30 µl 
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one hour in the dark at room temperature. Finally, the cells were washed three 
times in 1 ml PBS and once with dH2O and let to air-dry before mounting the 
coverslips on microscopy slides using Mowiol (10 % Mowiol, 25 % glycerol in 0.1 
M Tris-HCl pH 8.5) containing 1 µg/ml DAPI for nuclei staining.  
Table 4. Antibodies used for immunocytochemistry and their concentration. Primary antibodies used for 
specific protein labelling in immunocytochemistry experiments and their correspondent secondary antibody. 
The dilution in PBS + 1 % BSA from the commercial stock is specified. 
2.6.2 Imaging and analysis 
Most images were acquired with a 63x objective on the Zeiss LSM 710 
confocal microscope (Technology Facility in the Department of Biology in the 
University of York) using the ZEN 2009 software. Images for quantification 
analysis were taken with a 40x objective on a Nikon TE 200 wide-field 
fluorescence inverted microscope using a QImaging RoleraXR CCD camera and 
the SimplePCI software (Hamamatsu).  
Quantitative image analysis was performed using ImageJ. In order to 
compare the distribution of Src and RhoB throughout the cell, a five pixels width 
line was drawn across the diameter the cell, through the centre of the nucleus and 
perpendicular to the perinuclear region. The intensity of the fluorescent signal was 
measured for each pixel in the line and presented as the mean value of the five 
pixels along the line width. The analysis was performed on cells from 30 pictures 
per condition, from which mean values were calculated. Values were normalized 
to eliminate differences in overall intensity between cells. Statistical analysis of 
neurite quantification data used a Chi squared test with Bonferroni correction for 
the percentage of cells with neurites, and Kruskal-Wallis test for the number of 
neurites per cell. 
Primary antibody Secondary antibody 
Antibody Dilution Antibody Dilution 
α-FLAG (M2) 1:3,000 α-mouse ALEXA 594 / α-mouse ALEXA 488 1:500 
α-HA 1:1,000 α-mouse ALEXA 488 1:500 
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2.7 Immunoprecipitation (IP) 
Each 75 cm2 flask was washed three times with PBS before addition of 1 ml 
RIPA buffer (10 mM Tris-HCl pH 8, 1 mM EDTA, 0.5 mM EGTA, 1 % triton X-100, 
0.1 % sodium deoxycholate, 0.1 % SDS, 140 mM NaCl) containing 0.1 % β-
mercaptoethanol, 0.1 % protease inhibitors and 1 mM sodium orthovanadate. 
Buffers and samples were kept on ice during the whole process. The cells were 
scraped from the bottom of the flask using a cell scraper, transferred to an 
Eppendorf tube and incubated for 10 min at 4 ºC. The lysates were spun at 16,000 
g for 10 min at 4 ºC to remove the insoluble fraction. A Bradford assay was then 
performed to determine protein concentration and allow equal amounts of protein 
to be used for each sample. Approximately 200 µl of the lysate was reserved as 
‘input’. In the case of IPs performed with FLAG antibody-conjugated or 
phosphotyrosine antibody-conjugated beads, 15 µl of beads were washed three 
times in RIPA buffer (with quick spins at 4 ºC) and added to 1 ml of lysate. The 
tubes were incubated on a rotating wheel overnight at 4 ºC. For IPs in which 
beads and antibody were added separately, 1 ml of cell lysate was incubated with 
5 µg of antibody overnight on a rotating wheel at 4 ºC. 15 µl of protein G beads 
were added for another one hour incubation to recover immune complexes. 
The following day, the beads were pelleted for 5 min at 4 ºC at 720 g. The 
supernatant was reserved for assessing the efficiency of the IP. The washing and 
elution steps were performed using centrifuge tube filters of 0.45 µm (Spin-X, 
Costar), which had previously been washed twice with RIPA buffer. The beads 
were washed three times in 500 µl of RIPA buffer by pulsing for 30 s in a 
microcentrifuge at 4 ºC. For elution, 30 µl of elution buffer (0.125 M Tris-HCl, 4 % 
SDS, 20 % glycerol, pH 6.8) was added to the filter tubes and incubated for 10 min 
on a rocking platform at room temperature. The tubes were then centrifuged for 10 
min at 16,000 g and the eluate stored at -20 ºC.  
2.8 SDS-PAGE and Western blotting 
2.8.1 Sample preparation 
Inputs of IP experiments were diluted in 2x Laemmli buffer (4 % SDS, 20 % 
glycerol, 10 % β-mercaptoethanol, 0.004 % bromophenol blue and 0.125 M Tris-
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HCl) before gel electrophoresis. 10 % β-mercaptoethanol and 0.004 % 
bromophenol blue were added to eluted samples from IPs. All samples were 
boiled for 10 min at 95 ºC before loading. 
2.8.2 SDS-PAGE 
SDS-PAGE was used to separate proteins. Polyacrylamide gels were 
composed of a resolving gel (375 mM Tris-HCl pH 8.8, 0.1% SDS, 10 % 
acrylamide/bisacrilamide, 0.05% APS, 0.01% TEMED in dH2O) and a stacking gel 
(125 mM Tris-HCl pH 6.8, 0.1 % SDS, 4 % acrylamide, 0.05 % APS, 0.01 % 
TEMED in dH2O). Samples were loaded into the gel immersed in running buffer 
(250 mM Tris, 1.92 M glycine, 1 % SDS in dH2O) and run at 180 V until the dye 
front reached the bottom of the gel (around 45 min). Molecular weight markers 
were loaded next to the samples. 
2.8.3 Protein transfer 
Proteins were transferred from acrylamide gels to polyvinylidene difluoride 
(PVDF) membranes. The PVDF membrane was activated in 100 % methanol for 1 
min and then equilibrated along with the gel in transfer buffer (25 mM Tris, 190 
mM glycine, 20 % methanol) for 5 min. The gel and the membrane were placed in 
the cassette between pieces of 3MM paper and pads soaked in transfer buffer. 
The assembly was placed in the transfer cell so that the membrane was facing the 
positive electrode. The transfer was performed at 66 V for one hour or 20 V 
overnight. The membrane was stained with Ponceau red (0.1 % Ponceau S, 5 % 
acetic acid in dH2O) to confirm the correct transfer of proteins. 
2.8.4 Western blotting 
The membrane was blocked for one hour with 3 % skimmed milk (Marvel) 
in PBS or 3 % BSA in PBS when using α-phosphotyrosine antibodies to avoid 
detection of phosphoproteins present in milk. Incubation with the primary antibody 
was carried out for 2 h at room temperature or overnight at 4 ºC with shaking. 
Primary antibodies were diluted in PBS as specified in Table 5. After washing 
three times in washing buffer (PBS with 0.5 % Tween), the membrane was 
incubated for one hour at room temperature with shacking with an HRP-
conjugated secondary antibody. Secondary antibodies were diluted in PBS with 3 
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% skimmed milk or BSA, and 0.5 % Tween-20 (Table 5). The membrane was then 
washed three times for 10 min and incubated for 1 min with Immobilon 
Chemiluminescent HRP Substrate before immediate exposure to an 
autoradiography film that was then developed. Exposure times varied from 10 s to 
10 min depending on the intensity of the signal. To strip a membrane for reprobing 
with a different antibody, it was incubated for 30 min at room temperature with 
stripping buffer (136 mM NaCl, 20 mM glycine, pH 2.5) and washed in dH2O for 15 
min. When appropriate, the intensity of the bands was quantified by densitometry 
analysis using ImageJ. 
Table 5. Antibodies used for Western blotting and their concentration. Primary antibodies used for 
specific protein labelling in Western blotting experiments and their correspondent secondary antibody. Dilution 
of the commercial stock was made in PBS for primary antibodies and in PBS + 3 % milk or BSA + 0.5 % 
Tween-20 for secondary antibodies. 
  
Primary antibody Secondary antibody 
Antibody Dilution Antibody Dilution 
α-FLAG 1:1,000 α-mouse IgG HRP 1:5,000 
α-HA 1:10,000 α-mouse IgG HRP 1:5,000 
α-Sec23 1:1,000 α-rabbit IgG HRP 1:5,000 
α-pY20 1:1,000 α-mouse IgG HRP 1:5,000 
α-actin 1:1,000 α-mouse IgG HRP 1:5,000 
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Chapter 3. Results 
3.1 N2-Src enhances neuroblastoma differentiation and binds 
and phosphorylates COPII proteins 
3.1.1 N2-Src induces neurite outgrowth in cultured neuroblastoma cells 
As stated in section 1.2, N2-Src is thought to induce differentiation of 
neuroblastoma cells. N2-Src has indeed been demonstrated to promote the 
extension of neurite-like processes (from now on referred to as neurites) in 
neuroblastoma cell lines (Lewis, 2014). In order to confirm these results, 
neuroblastoma SK-N-AS cells were transfected with a Cherry-tagged N2-Src 
plasmid or a control plasmid. The cells were analysed four days after transfection 
to allow sufficient time for neurite extension in a cell type that is intrinsically 
resistant to differentiation. Quantification of neurites showed that 38 % of cells with 
overexpressed N2-Src had neurites compared to 19 % in control cells (Figure 6B). 
There was also a 14 % increase in the number of neurites when looking at the 
cells with at least one neurite (Figure 6B). In addition to having a higher number of 
neurites, these cells were observed to be smaller and more elongated (Figure 6A), 
which indicates a similar behaviour to differentiating neuronal cells. This result 
agrees with those of Lewis (2014) and confirms a role for N2-Src in the acquisition 
of neuronal morphology. Importantly, neurite outgrowth in SK-N-AS cells is a 
quantifiable feature that can be used for the study of N2-Src induced 
neuroblastoma differentiation.  
 
Figure 6. N2-Src overexpression increases neurite outgrowth in SK-N-AS cells. (A) Representative 
images taken on the fluorescence microscope are shown for Cherry (Control) and N2-Src-Cherry 
overexpressing cells. (B) Graphs showing quantification of neurites expressed as percentage of cells with 
neurites, and as the number of neurites in cells that present one neurite at least. The number of cells that 
were counted for each condition is indicated above each bar in the graph. 
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Interestingly, in our laboratory, COS7 cells have also been shown to 
increase their number of neurites upon N2-Src overexpression. COS7 cells 
provide a useful non-neuronal model system that is well characterised and easy to 
manipulate, and that has also been used in this study (see section 3.3). 
3.1.2 N2-Src overexpression induces Sec23A enrichment in a 
phosphotyrosine immunoprecipitation 
As extensively described in section 1.5, a link between N2-Src 
overexpression and tyrosine phosphorylation of a complex containing COPII 
proteins was established using phosphoproteomics. Components of the COPII 
complex were found to be enriched in a pY-IP from N2-Src overexpressing cells 
(Lewis, 2014). This experiment was performed using a HeLa cell line that inducibly 
expressed N2-Src-FLAG (iN2-Src cells) in response to doxycycline. This cell line 
was well characterised and observed to display neuronal differentiation-related 
features upon N2-Src overexpression, such as cell elongation, reduced 
proliferation and reduced migration (Lewis, 2014). Although they undergo changes 
in cell shape, iN2-Src HeLa cells do not grow neurites and thus are not appropriate 
for morphological analysis. However, they are a very useful tool for studying 
protein-protein interactions and protein phosphorylation in response to N2-Src 
overexpression. 
In order to confirm the results of the previous phosphoproteomic analysis, a 
pY-IP was performed from iN2-Src HeLa cells cultured in the presence or absence 
of doxycycline. In addition, cells were transfected with HA-tagged Sec13 to 
increase the amount of potentially co-immunoprecipitating COPII proteins. The cell 
samples were analysed by SDS-PAGE and Western blotting. N2-Src was shown 
to be highly expressed in doxycycline treated cells, whereas no N2-Src was 
detected in control cells, demonstrating the specificity of the cell line expression 
inducing system (Figure 7A). As expected, tyrosine phosphorylated proteins were 
more abundant in doxycycline treated cells, as shown by an α-pY antibody (Figure 
7A). An α-HA antibody was used to detect HA-Sec13. Surprisingly, HA-Sec13 
could not be detected in the IP despite its high abundance in the input (Figure 7A). 
Sec13 seems to be not tyrosine phosphorylated or bound to a tyrosine 
phosphorylated protein with a high enough affinity to be immunoprecipitated in a 
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detectable amount. Conversely, endogenous ~86 kDa Sec23A was detected and 
notably enriched in the pY-IP of N2-Src-FLAG overexpressing cells (Figure 7A). 
There was a 7.4 fold increase in pY-Sec23A according to densitometry 
quantification (Figure 7B). This result suggests that either Sec23A itself or a 
Sec23A binding protein has an increased tyrosine phosphorylation in the presence 
of overexpressed N2-Src.  
 
Figure 7. N2-Src overexpression enriches Sec23A in a pY-IP. (A) HeLa cells that inducibly express N2-
Src-FLAG when induced with doxycycline were transfected with HA-Sec13 and cultured in the presence or 
absence of doxycycline for two days before lysis. The lysate (input) was incubated with α-pY resin from which 
bound proteins were eluted (IP: pY). 1 % of input samples and 50 % of IP samples were run in a 
polyacrylamide gel and a Western blot was performed to analyse the samples using α-Sec23A, α-HA, α-
FLAG, α-pY20 and α-actin antibodies. The arrowhead indicates the band that corresponds to ~86 kDa 
Sec23A. Actin was used as a loading control. (B) Graph showing quantification by densitometry of Sec23A 
bands in the pY-IP for doxycycline treated and non-treated cells, normalized to actin bands of the 
correspondent condition in the input.  
3.1.3 COPII proteins bind N2-Src 
The enrichment of COPII proteins in the pY-IP from iN2-Src cells (section 
1.5) led us to hypothesize that there was an interaction between N2-Src and 
members of this complex. For that reason, the presence of a physical interaction 
was explored in a first approach to further investigate the link between N2-Src and 
COPII. This was achieved by performing several IPs from iN2-Src HeLa cells, 
which were used again as the model system. Sec13 and Sec23 served as model 
COPII coat components. 
iN2-Src HeLa cells were transfected with HA-Sec13, lysed after two days 
and incubated with α-FLAG beads. Western blot analysis with an α-HA antibody 
showed that HA-Sec13 was immunoprecipitated only in doxycycline treated cells, 
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which were confirmed to express N2-Src-FLAG (Figure 8A). This result implies 
that Sec13 and N2-Src form part of the same protein complex in the cell. A similar 
experiment was then performed on HA-Sec23A transfected cells. Unfortunately, 
HA-Sec23A was not detectable in the input of an α-HA blot (data not shown), 
probably due to low cell transfection efficiency. However, reprobing with an α-
Sec23A antibody revealed a faint band in doxycycline treated cells, which 
expressed N2-Src-FLAG (Figure 8B). Therefore, Sec23A and Sec13 can partake 
in complexes with N2-Src-FLAG in cells. 
 
Figure 8. Sec13 and Sec23A bind N2-Src. HeLa cells that inducibly express N2-Src-FLAG when treated with 
doxycycline were transfected with HA-Sec13 (A) or HA-Sec23A (B) and cultured in the presence or absence 
of doxycycline for two days before lysing them. α-FLAG beads were used to immunoprecipitate N2-Src-FLAG 
and its binding proteins from cell lysates. 0.5 % of input samples and 50 % of IP samples were run in a 
polyacrylamide gel and analysed by Western blotting by probing with α-HA, α-Sec23A, α-FLAG and α-actin 
antibodies. Actin was used as a loading control. 
To confirm the interaction between Sec23A and N2-Src, the complementary 
IP was performed, to detect the presence of N2-Src-FLAG in an HA-IP from HA-
Sec23A overexpressing cells. No N2-Src-FLAG was detected in the IP sample of 
any condition, despite the large amount detected in input samples and the high 
enrichment of HA-Sec23 in IP samples (Figure 9A). 
However, blotting with an α-pY antibody revealed a tyrosine phosphorylated 
protein that corresponded to the overexpressed HA-Sec23A, as confirmed by re-
probing the same PVDF membrane with an α-HA antibody (Figure 9A). Therefore, 
Sec23A contains at least one tyrosine that is phosphorylated in cells. Furthermore, 
the intensity of the pY-Sec23A signal (normalised to total HA-Sec23A) was 28 % 
stronger in doxycycline treated cells (Figure 9B), suggesting N2-Src expression 
increases Sec23A tyrosine phosphorylation. This experiment has only been 
performed once and must therefore be repeated to confirm these potentially 
exciting findings. 
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Figure 9. N2-Src is not detected to bind Sec23 and tyrosine phosphorylated HA-Sec23A is slightly 
increased in N2-Src overexpressing cells. HeLa cells that inducibly express N2-Src-FLAG when treated 
with doxycycline were transfected with HA-Sec23A and cultured in the presence or absence of doxycycline for 
two days before lysing them. Cell lysates were then incubated with α-HA beads in order to enrich HA-Sec23. 
0.5 % of input samples and 50 % of IP samples were run in a polyacrylamide gel and analysed by Western 
blotting by using α-pY20, α-HA and α-FLAG antibodies. (A) Blots showing pY proteins, HA-Sec23 and N2-Src-
FLAG for the three conditions. Arrowhead indicates the band that corresponds to FLAG-N2-Src, in order to 
differentiate it from a lower band at 50 kDa that is likely to belong to the heavy chain of the beads-conjugated 
antibody. (B) Densitometry quantification of Sec23A in the pY20 blot, in control cells and N2-Src 
overexpressing cells (first and third condition, respectively). Intensity of Sec23A bands in the pY20 blot was 
normalized to that of Sec23A bands in the HA blot, and expressed as fold increase. 
3.2 Overexpressed N2-Src induces dispersion of ERES 
Biochemical approaches thus far point to an N2-Src-COPII interaction that 
takes place in cells. With the purpose of understanding how this interaction might 
be occurring, the cellular localisation of N2-Src and the COPII component Sec23A 
was studied in COS7 cells. COS7 cells represent a useful model for the study of 
neuronal differentiation upon N2-Src overexpression, as they are capable of 
extending processes that would be equivalent to the neurites of neuronal cells. All 
presented pictures were taken with a confocal microscope to ensure the precise 
detection of colocalisation. 
3.2.1 N2-Src induces dispersion of Sec23A-labelled ERES  
Overexpressed N2-Src-Cherry was mainly located in a perinuclear region in 
COS7 cells, with some presence at the plasma membrane (Figure 10A). N2-Src-
Cherry appeared to decorate small vacuole-like structures in some areas of the 
cytoplasm (high magnification inserts in Figure 10A, C2). Overexpressed HA-
Sec23A displayed a punctate pattern typical of COPII proteins (Figure 5B; Kirk and 
Ward, 2007). These puncta correspond to ERES, which contain all COPII 
components. ERES were observed throughout the cell, but there was a 
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concentration of staining in a small, distinct region adjacent to the nucleus (Figure 
10B). 
Co-expressed HA-Sec23A and N2-Src-Cherry were located in different 
structures, as they did not colocalise despite being in the same area (Figure 10C). 
This can be appreciated in high magnification images in Figure 10C2, where 
Sec23A puncta appear to surround N2-Src-labelled circular structures but are not 
found overlapping with them. Interestingly, N2-Src-Cherry overexpression had an 
effect on HA-Sec23A localisation. Cells that expressed N2-Src-FLAG had diffuse 
HA-Sec23A-labelled ERES that were no longer enriched in a perinuclear region, 
but more homogeneously distributed throughout the cytoplasm where N2-Src was 
present (Figure 10B, C). The area containing dispersed ERES seems to 
correspond to that of N2-Src (Figure 10C). The number of cells in which ERES 
were dispersed was quantified for Cherry and N2-Src-Cherry overexpressing cells. 
There were 46 % more cells showing a dispersed ERES phenotype in N2-Src 
overexpressing cells, in which only 33 % had normal ERES distribution (Figure 
10D). N2-Src is therefore affecting ERES distribution. 
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Figure 10. N2-Src induces ERES dispersion in the perinuclear region. (A-C1) COS7 cells were 
transfected with a HA-Sec23A or a control plasmid, and with an N2-Src-Cherry or a control Cherry plasmid. 
Two days after transfection, the cells were fixed and stained with α-HA mouse primary antibody, ALEXA 488 
α-mouse secondary antibody and nuclear DAPI staining before visualization under a confocal microscope. 
Representative pictures are shown. Amplified sections of some pictures are shown. Scale bar represents 20 
µm. (C2) Magnified pictures of the indicated sections in C1. (D) Cherry and N2-Src-Cherry overexpressing 
cells were classified according to the distribution of HA-Sec23A puncta (ERES) in the perinuclear region. 
Percentage of cells with a dispersed ERES phenotype was plotted. 30 40x fields of view were examined per 
condition, corresponding to approximately 100 control and 50 N2-Src expressing cells. Results are means 
from two independent experiments. 
3.2.2 N2-Src is associated with endosomal membranes 
The fact that N2-Src is localised in the perinuclear region but does not 
colocalise with ERES raised the question of where the putative interaction 
between N2-Src and the COPII complex might be occurring. Whereas COPII 
organelle localisation has been extensively studied, that of N2-Src is unknown. C-
Src localisation has been previously analysed and was used to give insight into 
that of N2-Src. C-Src-Cherry and N2-Src-FLAG were co-expressed in COS7 cells 
in order to compare their localisation. They were observed to colocalise in the 
perinuclear region and also in other areas such as the plasma membrane (Figure 
11A). Colocalisation was clearly observed in magnified images (Figure 11A). 
Src proteins are able to bind and trans-phosphorylate (Vojtěchová et al., 2006) 
and could therefore be chaperoning each other to the same site in co-transfected 
cells. In order to avoid C-Src and N2-Src influencing each other’s localisation, their 
cellular distribution was further analysed in cells that overexpressed them 
independently. A line was drawn in 65 cells of each condition along the cell 
diameter through the centre of the nucleus and of the perinuclear region in which 
Srcs accumulate, as outlined in Figure 11B. The fluorescence intensity for each 
protein was measured along the line as explained in the methods section (2.6.2) 
and plotted. Cellular distribution of C-Src-Cherry and N2-Src-FLAG was shown to 
be very similar (Figure 11C). There was an intensity peak at the centre of the cell 
that can be interpreted as the perinuclear region (Figure 11C). N2-Src-FLAG was 
less concentrated in the periphery of the cell, reaching a maximum 15 % 
difference with C-Src (Figure 11C). This could mean that the accumulation of N2-
Src in the perinuclear region is more pronounced than for C-Src, although a 
different behaviour due to the different tags cannot be dismissed. 
 42 
 
Figure 11. C-Src and N2-Src colocalise. COS7 cells were transfected with C-Src-Cherry or an empty Cherry 
plasmid, and with N2-Src-FLAG or an empty FLAG plasmid. Two days after transfection the cells were fixed 
and stained with a mouse α-FLAG primary antibody and an ALEXA 488 α-mouse secondary antibody. The 
cells were visualized in a confocal microscope. (A) Representative pictures of each condition are presented. 
Cherry is shown in red, FLAG in green. Colocalisation appears in yellow in merge images. Magnification of 
perinuclear sections is shown to point out structures that were labelled with both C-Src and N2-Src and 
therefore prove their colocalisation. Scale bar represents 20 µm. (B) Line drawn across the diameter of a 
schematic cell, through the centre of the nucleus and the perinuclear region were Src fluorescent signal 
intensity is the highest. (C) Fluorescence signal intensity corresponding to C-Src or N2-Src was measured 
along a line drawn in 65 cells as in (B). Mean values of 65 cells from one experiment were normalised and the 
fluorescent signal intensity was plotted for each pixel along the line length. 
Sandilands et al. (2004) demonstrated that perinuclear C-Src was 
contained in endosomes that mediated its transport to the plasma membrane upon 
activation. These endosomes also contained the small GTPase RhoB, which was 
necessary for C-Src transport. As N2-Src has a similar distribution to C-Src, it was 
possible it would be found in the same endosomes. In order to test this, COS7 
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cells were transfected with GFP-RhoB and C-Src-FLAG or N2-Src-FLAG, and 
analysed under the confocal microscope. 
As expected, C-Src-FLAG and GFP-RhoB colocalised in the perinuclear 
region of cells and also in some regions of the plasma membrane and in elongated 
structures in the cytoplasm (Figure 12A). Importantly, a partial overlap with RhoB 
was observed in the case of N2-Src-FLAG (Figure 12A), suggesting that at least 
part of the N2-Src accumulation in the perinuclear region corresponds to an 
endosomal localisation. Plasma membrane and cytoplasmic structures containing 
both GFP-RhoB and N2-Src-FLAG were also observed (Figure 12A). 
Magnification of the images allowed the identification of structures labelled with 
both Src and RhoB (Figure 12A).  Whether these elongated structures are tubular 
extended endosomes is not certain. These results were confirmed by analysing 
the distribution of fluorescent signal intensity in C-Src-Cherry or N2-Src-FLAG and 
GFP-RhoB cotransfected cells. The signal intensity was measured along a line 
that was drawn across the cell, through the centre of the nucleus and of the 
perinuclear region where RhoB-GFP staining was concentrated, as outlined in 
Figure 12B. This analysis was performed in 80 C-Src-FLAG and GFP-RhoB 
expressing cells and in 66 N2-Src-FLAG and GFP-RhoB expressing cells. Mean 
values were calculated and normalised as explained in the methods section 
(2.6.2), and plotted. The distribution of GFP-RhoB was shown to match that of C-
Src-FLAG and N2-Src-FLAG (Figure 12A), which implies that N2-Src has an 
endosomal localisation and a transport mechanism to the periphery of the cell 
similar to C-Src. 
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Figure 12. Both C-Src and N2-Src colocalise with RhoB. COS7 cells were transfected with a C-Src-FLAG, 
N2-Src-FLAG or empty FLAG plasmid, and with a RhoB-GFP or CFP plasmid. Two days after transfection the 
cells were fixed and stained with a mouse α-FLAG primary antibody and an ALEXA 594 α-mouse secondary 
antibody. The cells were visualized in a confocal microscope. (A) Representative pictures of each condition 
are presented. FLAG is shown in red, CFP in cyan and GFP in green. Colocalisation appears in yellow in 
merge images. Magnification of perinuclear sections of some images is shown to point out labelling of the 
same structures by Src and RhoB. Scale bar represents 20 µm. (B) Line drawn across the diameter of a 
schematic cell, through the centre of the nucleus and perpendicular to the perinuclear region were RhoB 
signal is the highest. (C) Intensity of fluorescence corresponding to C-Src and RhoB or N2-Src and RhoB was 
measured along a line drawn as in (B) in 43 cells per condition. Mean values of 43 cells per condition from 
one experiment were normalised to 100 and fluorescent signal intensity was plotted for each pixel in the line 
for C-Src+RhoB and N2-Src+RhoB conditions.  
3.3 Overexpression of COPII proteins perturbs N2-Src-dependent 
neurite outgrowth 
Our ultimate goal was to study the involvement of the COPII complex in N2-
Src induced neuroblastoma differentiation. The detection of an interaction does not 
functionally link them, and the induction of ERES dispersion by N2-Src has not 
been proven to be of physiological relevance. For that reason, we analysed the 
effect of overexpressing Sec13 and Sec23A, used as model COPII proteins, in the 
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induction of neurites by N2-Src in COS7 and SK-N-AS cells. Cells were 
transfected with plasmids expressing N2-Src-Cherry or Cherry (control) and HA-
Sec13 or HA-Sec23A.  
Two days following transfection, COS7 cells were processed for 
immunofluorescence analysis. COS7 have a tendency to spontaneously extend 
processes and therefore the criteria defining a neurite process were strict and only 
processes that were approximately 2 µm wide and longer than the cell diameter 
were included in the analysis (Tojima et al., 2000). HA-Sec13 and HA-Sec23A 
overexpressing cells showed a similar phenotype to control cells that 
overexpressed Cherry only (Figure 13A). Around 20 % of these cells presented 
neurites and the number of neurites per cell was approximately 1.4 (Figure 13C). 
As expected, N2-Src-Cherry overexpressing cells presented neurites more 
frequently and in higher numbers than control cells (Figure 13B). Two days of N2-
Src-Cherry overexpression caused a significant 128 % increase in the number of 
cells with neurites and a 24 % increase in the number of neurites per cell (cells 
without neurites were not included), when compared to control cells (Figure 13C). 
Surprisingly, co-expression of either HA-Sec13 or HA-Sec23A with N2-Src-
Cherry decreased neurite outgrowth with respect to N2-Src-Cherry overexpressing 
cells (Figure 13B). Compared to this control, there was a 20 % and a significant 24 
% reduction in the number of cells with neurites when co-expressing N2-Src with 
HA-Sec13 and HA-Sec23A, respectively (Figure 13C). The number of neurites per 
cell was restored by HA-Sec13 or HA-Sec23A co-expression: from 1.6 in N2-Src 
overexpressing cells to 1.3, that is, to similar levels to those in control cells (Figure 
13C). Some of the differences were probably not significant because of the low 
number of cells that were analysed. 
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Figure 13. Sec13 and Sec23A overexpression affect neurite outgrowth induced by N2-Src in COS7 
cells. COS7 cells were transfected with an N2-Src-Cherry or control Cherry plasmid, and with a HA-Sec13, 
HA-Sec23A or control plasmid. Two days after transfection, the cells were fixed, stained and mounted. The 
antibodies that were used were α-HA mouse primary antibody and ALEXA 488 α-mouse secondary antibody. 
(A, B) Representative pictures taken in a wide field fluorescence microscope are shown for each condition. 
(C) Quantification of neurites in cells of each condition, expressed as percentage of cells that presented 
neurites and as number of neurites per cell. 60 40x fields of view were analysed per condition from two 
independent experiments. The exact number of cells analysed for each condition is stated above the 
corresponding graph bar. Chi squared test on the percentage of cells with neurites data showed that there 
were significant differences between conditions (p-value=4.3E-7). Chi squared test, with Bonferroni correction, 
showed that the percentage of cells with neurites in N2-Src cells is significantly higher than in control (p-
value=3.5E-3) and Sec13+N2-Src cells (p-value=4.24E-5). Statistical analysis on the neurites per cell data by 
Kruskal-Wallis test showed significant differences between N2-Src and control, Sec13 (p-value<0.05) and 
Sec23A cells (p-value<0.05), but not between N2-Src and Sec13+N2-Src or Sec23A+N2-Src cells. Error bars 
indicate the Standard Error of the Mean from two independent experiments. 
In the case of neuroblastoma SK-N-AS cells, the cells were analysed four 
days after transfection and the criteria to define neurites was less strict; every 
process that protruded from the cell body was considered a neurite. Interestingly, 
the results from COS7 cells were confirmed. The percentage of N2-Src-Cherry 
overexpressing cells with neurites was 133 % significantly higher than in control 
cells (Figure 14). Cells that co-expressed both N2-Src-Cherry and any of the 
COPII components showed neurites with lower frequency (Figure 14B). There was 
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a 29 % and a significant 65 % reduction in HA-Sec13 and HA-Sec23A co-
overexpressing cells, respectively (Figure 14C). There was, however, not a big 
reduction in the number of neurites per cell and no statistically significant 
variations between samples, presumably due to the small proportion of cells that 
presented neurites (Figure 14C). Inhibition of N2-Src-induced neurite outgrowth by 
Sec13 or Sec23A overexpression in COS7 and SK-N-As cells provides a 
tantalising suggestion that COPII transport is involved in N2-Src-dependent 
neuroblastoma differentiation.  
 
Figure 14. Sec13 and Sec23A overexpression affect neurite outgrowth induced by N2-Src in SK-N-AS 
cells. SK-N-AS cells were transfected with an N2-Src-Cherry or control Cherry plasmid, and with a HA-Sec13, 
HA-Sec23A or control plasmid. Four days after transfection, the cells were fixed, stained and mounted. The 
antibodies that were used were α-HA mouse primary antibody and ALEXA 488 α-mouse secondary antibody. 
(A, B) Representative pictures taken in a wide field fluorescence microscope are shown for each condition. 
(C) Quantification of neurites in cells of each condition, expressed as percentage of cells that presented 
neurites and as number of neurites per cell. 30 40x fields of view were analysed per condition from one 
experiment. Chi squared test on the percentage of cells with neurites data showed that there were significant 
differences between conditions (p-value=0.01). Chi squared test, with Bonferroni correction, showed that the 
percentage of cells with neurites in N2-Src cells was significantly higher than in control (p-value=3E-4) and 
Sec23+N2-Src cells (p-value=1.33E-2). Statistical analysis on the neurites per cell data by Kruskal-Wallis test 
showed no significant differences between any of the conditions. Error bars represent standard deviation. 
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Chapter 4. Discussion 
N2-Src is a tyrosine kinase known to be involved in the development of the 
nervous system. Its high expression has been shown to correlate with the 
differentiation of neuroblastoma cells in vivo and in culture (Matsunaga et al., 
1993). However, its mechanism of action remains unknown. In this study, I have 
further investigated the implication of the COPII complex in N2-Src induced 
differentiation of neuroblastoma cells, which had been previously proposed (Lewis, 
2014). N2-Src and COPII components Sec13 and Sec23A were demonstrated to 
form part of a common protein complex in cells. N2-Src overexpression was 
verified to increase tyrosine phosphorylation of a Sec23A-containing protein 
complex, and a preliminary experiment suggested that Sec23A tyrosine 
phosphorylation is directly induced by N2-Src. In addition, N2-Src was shown to 
locate mainly at perinuclear endosomes and to promote dispersion of Sec23A-
labelled ERES throughout the cytoplasm when overexpressed. In addition, the 
involvement of the COPII complex in the acquisition of neuronal morphology 
induced by N2-Src was tested in neuroblastoma cells. Overexpression of Sec13 or 
Sec23A does not notably affect neurite outgrowth in neuroblastoma cells under 
basal conditions, but it significantly reduces the ability of N2-Src to induce this 
process. Overall, these results support the hypothesis that N2-Src induced 
differentiation of neuroblastoma cells occurs through the regulation of transport in 
COPII vesicles. 
4.1 N2-Src binds and phosphorylates COPII proteins 
N2-Src overexpression in HeLa cells had previously been shown to 
increase the amount of COPII components in a pY-IP by mass spectrometry 
analysis (Lewis, 2014). Sec16A, Sec23A, Sec23B, Sec24B and Sec24C were the 
COPII components most enriched in N2-Src samples when compared to control 
samples (Figure 4; Lewis, 2014). In this study, Sec23A was confirmed to be 
enriched in a pY-IP in HeLa cells by Western blotting (Figure 7). Very few 
interactions are known to occur between any of the COPII components and other 
proteins in the pY-IP (Lewis, 2014), which suggests that they are likely to be the 
proteins (or protein) that increase their tyrosine phosphorylation in the presence of 
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N2-Src. Therefore, they are all possible substrates of N2-Src, and since Sec23 
and Sec24 form a heterodimer for the constitution of the inner layer of the coat, it 
is not surprising that they were co-immunoprecipitated. The presence of Sec16A is 
also not surprising, as it functions as a scaffolding protein that interacts with all 
other COPII components. 
Here, the interactions between N2-Src and the COPII complex have been 
investigated. Sec23A was studied in particular because of its high enrichment in 
the mentioned phosphoproteomic analysis. Sec13 was also studied to allow the 
detection of an interaction of any COPII component with N2-Src, as the presence 
of only one Sec13 isoform in mammalian cells means that it can bind to all 
isoforms of the remaining COPII components. The disruption of COPII transport in 
Sec13-silenced cells has demonstrated its essential role (Stephens, 2003). This 
study has shown the presence of Sec13 and Sec23A in an N2-Src IP from HeLa 
cells (Figure 8), demonstrating that N2-Src and COPII components form a 
complex in cells. It would be important to confirm the result by using a different 
method to Western blotting, such as mass spectrometry. As these experiments 
were performed with overexpressed proteins, the detection of endogenous 
proteins in the IPs would also be important. 
Unfortunately, HA-Sec23A failed to co-immunoprecipitate N2-Src (Figure 
9), which seems inconsistent with Sec23 immunoprecipitation by N2-Src. This 
result could be due to sensitivity issues or steric hindrance by the combination of 
tags. All protein-protein interaction experiments were performed in HeLa cells, 
which were shown to reduce migration, proliferation and to induce morphological 
changes upon N2-Src overexpression, in a process that seems to reproduce that 
in differentiating neuroblastoma cells (Lewis, 2014). However, the results obtained 
should be confirmed in a neuroblastoma cell line to ensure that the mechanism 
that is induced by N2-Src is conserved. 
Given the link between N2-Src overexpression and tyrosine 
phosphorylation of a complex that included COPII components, it was appropriate 
to specifically investigate the phosphorylation of COPII proteins. The availability of 
a Sec23A construct allowed me to search for differences in tyrosine 
phosphorylation of IP-enriched Sec23A in control and N2-Src overexpressing 
HeLa cells. Sec23A is tyrosine phosphorylated in the absence of N2-Src, as HeLa 
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cells do not normally express Src neuronal isoforms (Figure 9). Excitingly, the 
amount of tyrosine phosphorylated Sec23A was 28 % increased by N2-Src 
overexpression (Figure 9). This result should be taken with caution, as it is a small 
increase obtained from only one experiment. In vitro kinase experiments would 
confirm the result and directly test whether Sec23A is a substrate of N2-Src. Mass 
spectrometry analysis on Sec23A enriched samples should be performed in order 
to identify specific phosphorylated tyrosine residues. According to the 
PhosphoSitePlus database, two phosphotyrosines in Sec23A have been identified 
to date by high throughput mass spectrometry: p-Y348 (trunk region) and p-Y678 
(gelsolin-like domain; Hornbeck et al., 2014). Further experiments should be 
performed to test whether N2-Src can phosphorylate any of these tyrosine 
residues. As Y348 is located in the trunk region, which forms the Sec23/Sec24 
dimer interface (Lederkremer et al., 2001), the putative phosphorylation of Sec23A 
Y348 by N2-Src could therefore be affecting Sec24 binding. Importantly, the 
Sec23/Sec24 dimer is responsible for cargo recognition and binding (Aridor et al., 
1998; Kuehn et al., 1998). Most cargo studied to date bind specifically to Sec24 
(Lee et al., 2004). However, Sec23A plays an essential role in cargo specificity, as 
it can bind different Sec24 isoforms that target distinct transport motifs (Mancias 
and Goldberg, 2008; Wendeler et al., 2007). As a consequence, distribution of 
Sec24 isoforms and therefore cargo specificity varies between ERES (Iwasaki et 
al., 2015). Furthermore, distribution of Sec24 isoforms in ERES varies in response 
to environmental changes (Iwasaki et al., 2015). Existing regulation of the 
Sec23/Sec24 dimer has been described via the Ser/Thr kinases Akt (Sharpe et al., 
2011) and CK1δ (Lord et al., 2011). In particular, Sec24C/D phosphorylation by 
Akt has been shown to hinder Sec23A binding (Sharpe et al., 2011). 
Other COPII components that could be targets for N2-Src include Sec16A, 
as it contains a central sequence with more than 15 phosphotyrosines identified by 
mass spectrometry, according to the PhosphoSitePlus database (Hornbeck et al., 
2014). This region of Sec16A is a proline-rich sequence, and therefore a possible 
binding partner of the Src SH3 domain. Conversely, Sec16A phosphorylation is 
implicated in the formation and organisation of ERES. Thus, based on our results 
and previous descriptions of COPII traffic control mechanisms, the most likely 
scenarios for COPII regulation by N2-Src would be the regulation of cargo 
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specificity through Sec23/Sec24 phosphorylation, or the regulation of ERES 
formation through Sec16A phosphorylation. 
4.2 N2-Src induces ERES redistribution and is located in 
perinuclear endosomes 
The association of N2-Src and the COPII complex has been studied by 
immunocytochemistry in COS7 cells. N2-Src was observed in the periphery of 
circular compartments in the cytoplasm (Figure 10), and COPII components were 
concentrated at ERES, where the formation of COPII vesicles takes place (Kirk 
and Ward, 2007). Sec23A-labelled ERES were observed to be enriched in a 
specific area of the perinuclear region (Figure 10). This area has frequently been 
shown to colocalise with ERGIC markers (Budnik et al., 2011; Hughes and 
Stephens, 2008; Stephens, 2003; Townley et al., 2008), and is interpreted to 
correspond to the ER around the ERGIC (Johnson et al., 2015). 
Co-expressed N2-Src and Sec23A did not colocalise, despite being in the 
same area (Figure 10). ERES seemed to surround the N2-Src-labelled 
compartments (Figure 10). Interestingly, N2-Src overexpression caused a 
redistribution of ERES: in the presence of overexpressed N2-Src, ERES were no 
longer restricted to ERGIC-like staining but distributed in a larger perinuclear 
region, which matches with the region to which N2-Src is localised (Figure 10). 
This result suggests the capacity of N2-Src to recruit COPII components. It 
supports the hypothesis that N2-Src regulates the COPII complex through 
Sec16A, known to organize ERES formation and distribution (Connerly et al., 
2005; Watson et al., 2006; Yorimitsu and Sato, 2012). 
Where the interaction between N2-Src and COPII takes place is not 
obvious from these experiments. The fact that COPII components from different 
coat subunits co-precipitate N2-Src suggests that the interaction takes place 
where coat components are forming a complex. Therefore, N2-Src is likely to 
target its COPII substrate at the ERES. More information on N2-Src intracellular 
localisation was necessary to address this question. Co-expressed C-Src and N2-
Src were highly colocalised (Figure 11). As Src proteins are able to trans-
phosphorylate, the distributions of C-Src and N2-Src were studied in separate cells 
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in order to confirm their similarity in normal conditions. Indeed, the distribution 
along the cell diameter of the fluorescent signal corresponding to each protein was 
very similar (Figure 11), which suggests that C-Src and N2-Src are located in the 
same cellular structures. This fact allowed me to investigate N2-Src organelle 
localisation based on the already studied localisation of C-Src. 
C-Src is known to be membrane-associated both in the plasma membrane 
and in cytoplasmic organelles through a myristate in the SH4 domain (Resh, 
1994). Various perinuclear intracellular organelles containing C-Src have been 
proposed: nuclear envelope and reticular structures around the nucleus (Krueger 
et al., 1980), perinuclear vesicles (Redmond et al., 1992) and Golgi membranes 
(Bard et al., 2002). However, the consensus of more recent studies points towards 
an endosomal localisation of C-Src in basal conditions (Kaplan et al., 1992; 
Kasahara et al., 2007; Sandilands et al., 2004). These endosomes contain Rab11 
and are therefore likely to belong to the Endosome Recycling Compartment (ERC; 
Sandilands et al., 2004). When C-Src activation is triggered by mitogenic or 
integrin signaling in the plasma membrane (Roche et al., 1995), it is transported to 
the periphery of the cell (Kasahara et al., 2007; Timpson et al., 2001). The 
transport takes place in endosomes whose movement has been shown to be 
dependent on Rho GTPases (Gasman et al., 2003; Sandilands et al., 2004). 
Although C-Src is activated in response to different inputs, its translocation seems 
to be common in all of them. It is a process dependent on the SH3/SH2 C-Src 
domains, independent of the kinase domain and dependent on the actin 
cytoskeleton (Fincham et al., 1996).  
An endosomal localisation of N2-Src was suggested by a partial co-
localisation with RhoB in COS7 cells, which was also confirmed to occur in the 
case of C-Src (Figure 12). The distribution of signal intensity corresponding to the 
kinases and RhoB along the cell diameter was very similar (Figure 12). Negligible 
differences in the size of the perinuclear accumulation of RhoB and Srcs could be 
attributed to the different tags. Further experiments with markers from different 
organelles and in different cell types should be performed in the future to confirm 
endosomal localization of N2-Src and identify possible additional locations. An in-
depth analysis of N2-Src activation and translocation has not been performed. 
However, colocalisation with C-Src and RhoB in different cellular structures implies 
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that N2-Src and C-Src have a similar mechanism of transport from endosomes in 
the perinuclear region to the plasma membrane. More relevant to our research is 
the fact that N2-Src is associated with endosomal membranes. 
N2-Src showed a different localisation than Sec23A at ERES. As N2-Src 
seems to be around endosomal vesicles, it is possible that the interaction with the 
COPII complex takes place at the interface between the ER and endosomes. ER-
endosome contacts have been previously described by Rocha et al. (2009), who 
showed how the late endosome associated protein ORP1L changes its 
conformation according to cholesterol levels and mediates the interaction of ER 
protein VAP with a Rab7-RILP complex in endosomes. Another study by Raiborg 
et al. (2015) demonstrated the binding of ER resident protein protrudin with 
PtdIns(3)P in endosomal membranes, allowing the formation of contacts between 
the two organelles. Interestingly, protrudin overexpression increases the number 
of ER-endosome contacts (Raiborg et al., 2015), confirming a similar mechanism 
to that of ERES redistribution around overexpressed N2-Src. As an alternative to 
an interaction at ER-endosome contacts, N2-Src could be present on a type of 
organelle that was not tested by the immunofluorescence in this study. 
4.3 The COPII complex is involved in N2-Src induced 
neuroblastoma differentiation 
N2-Src overexpression promotes differentiation of cultured neuroblastoma 
cells, which was confirmed to occur in SK-N-AS cells by the increase in the 
percentage of cells with processes and in the number of processes per cell (Figure 
6). Processes outgrowth in COS7 cells or SK-N-AS cells was taken as the 
equivalent to neurite outgrowth in neuroblastoma cells that occurs in vivo. In this 
study, the involvement of the COPII complex in N2-Src induced neurite outgrowth 
has been demonstrated in COS7 and SK-N-AS cells. N2-Src overexpression was 
confirmed to significantly increase the percentage of cells with neurites in COS7 
(Figure 13) and SK-N-AS cells (Figure 14), and the average number of neurites in 
cells with at least one neurite in COS7 cells (Figure 13). Sec13 and Sec23A 
overexpressing cells showed a normal morphology and their neurite extension was 
not significantly different to control cells (Figure 13, Figure 14). Therefore, the 
overexpression of COPII components is compatible with cellular maintenance and 
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does not affect neurite outgrowth on its own. Unfortunately, the number of SK-N-
AS cells that presented neurites was too small for statistical analysis on the 
number of neurites per cell (Figure 14). It was surprising to observe diminished 
neurite outgrowth in cells that overexpressed Sec13 or Sec23A in addition to N2-
Src, when compared to N2-Src only overexpressing cells (Figure 13, Figure 14). 
The percentage of cells with neurites in Sec13 and N2-Src overexpressing COS7 
cells (Figure 14) was significantly smaller, as well as the percentage of cells with 
neurites in Sec23A and N2-Src overexpressing SK-N-AS cells (Figure 14). 
Strikingly, co-expression with Sec23A in SK-N-AS cells completely abolished 
neurite outgrowth induced by N2-Src, and control levels were restored (Figure 14).  
Inhibition of N2-Src-induced neurite outgrowth upon overexpression of 
Sec13 or Sec23A supports the involvement of COPII transport in neuronal 
differentiation. Given that the overexpression of COPII proteins alone does not 
inhibit basal neurite outgrowth, its effect is likely to be specific to the N2-Src 
induced pathway. The fact that the overexpression of COPII components 
decreases neurite outgrowth, instead of increasing it, appears to challenge our 
hypothesis that considers COPII transport as a positive factor mediating N2-Src 
neuroblastoma differentiation explained in section 1.6. Two possibilities can be 
drawn from this result. Firstly, overexpression of Sec13 or Sec23A could be 
increasing the rate of COPII vesicle formation, resulting in an inhibition of the N2-
Src pathway. In this case, N2-Src would be diminishing COPII transport rate 
during differentiation in order to stimulate the acquisition of neuronal morphology. 
However, there is no evidence that the overexpression of COPII proteins results in 
an increase in COPII vesicle traffic. Szczyrba et al. (2011) overexpressed Sec23A 
in carcinoma cells to show a reduction in cell growth and proliferation, but they did 
not demonstrate that this reduction was due to an increase in COPII traffic rate. In 
addition, the fact that Sec23A function depends on the availability of Sec24 and 
that Sec13 forms part of the outer layer of the coat argues against an overall 
increase in the formation of COPII vesicles. The other possibility is that the 
overexpression of Sec13 and Sec23A is not increasing the ER-ERGIC transport 
rate, but deregulating the process. It is plausible that the lack of balance between 
coat components at the ERES is impeding the correct formation of COPII vesicles 
or altering the subtle regulation of transport specificity. 
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Complementary experiments blocking COPII transport should be performed 
in order to discriminate between a positive or negative effect of the complex in N2-
Src induced differentiation. It could be achieved by Sec13 silencing, which has 
been previously shown to cause the accumulation of COPII proteins at ERES due 
to used disrupted COPII transport (Townley et al., 2008). In addition, knowing the 
specific protein and residue targeted by N2-Src would inform siRNA rescue 
experiments. If a non-phosphorylatable mutant substrate were able to rescue 
COPII protein transport but not neurite outgrowth upon N2-Src overexpression, the 
N2-Src induced differentiation pathway would be proven to involve the 
phosphorylation of that particular residue. It would also be appropriate to include 
markers of differentiation other than neurite outgrowth. Finally, it would be 
interesting to study the effect of COPII protein overexpression on neuroblastoma 
cell lines with a high intrinsic N2-Src expression that spontaneously differentiate. 
The involvement of COPII in the acquisition of neuronal morphology has 
formerly been shown: Drosophila homologs for Sar1 and Sec23 are necessary for 
correct dendritic growth, and the transport of specific markers to the plasma 
membrane of dendrites was impeded by Sar1 silencing (Ye et al., 2007); COPII 
components Sar1, Sec13, Sec31, Sec23 and Sec24 are transcriptionally 
upregulated to direct dendrite development (Iyer et al., 2013); and Sec24 is 
necessary for GABA transporter-1 axonal targeting (Reiterer et al., 2008). Other 
studies have linked the secretory pathway at post-Golgi stages to dendrite growth 
(Horton et al., 2005; Tang, 2008a). Horton et al. (2005) have, in addition, shown 
how the asymmetric growth of neurites depends on directed membrane traffic. 
Phospholipid and sphingolipid transport is particularly important in neuronal 
differentiation, as a great amount of membrane is required for the growth of 
neurites, dendrites and axons (Lecuit and Pilot, 2003). Particular sets of 
transmembrane and membrane-associated proteins, such as neurotransmitter 
receptors, adhesion proteins and axonal guidance proteins, must also be delivered 
for dendrite formation (Arimura and Kaibuchi, 2007; Tang, 2008b). The specific 
molecular mechanisms of secretory pathway regulation in the context of neuronal 
differentiation remain largely unknown. 
Based on the interpretation of results in this study, I propose a model for 
neuroblastoma differentiation through the regulation COPII vesicle transport by 
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N2-Src. In neuroblastoma cells with low N2-Src levels, ERES are mainly located in 
the ER surrounding the ERGIC and COPII vesicles transport molecules that 
maintain an undifferentiated state (Figure 15). Highly expressed N2-Src is located 
at endosomes and promotes the formation of ERES in the ER around them. N2-
Src interacts and phosphorylates COPII components, most likely Sec23A, Sec24 
or Sec16A, regulating the cargo specificity of COPII vesicle formation (Figure 15). 
N2-Src regulation of ER-ERGIC transport allows the delivery of molecules that 
promote neuronal differentiation to the periphery of the plasma membrane (Figure 
15). 
 
Figure 15. Proposed model for N2-Src induced neuronal differentiation in neuroblastoma cells. COPII 
vesicles are formed at ERES and transported to the ERGIC, from where cargoes continue their delivery to 
other organelles, like the plasma membrane. In the presence of low N2-Src levels, molecules that maintain an 
undifferentiated state are transported through the secretory pathway. In neuroblastoma cells in which N2-Src 
is highly expressed, ERES are redistributed around endosomal compartments and become accessible to N2-
Src. N2-Src binds and phosphorylates COPII components, modifying vesicle formation. As a consequence, 
the transport of membrane proteins and/or lipids through the secretory pathway is regulated to promote 
neurite outgrowth and other processes of neuronal differentiation. 
4.4 Implications for neuroblastoma differentiation treatment 
Despite advances in high-risk neuroblastoma treatment, only 40 % of 
patients survive. The neuroblastoma cells that remain after initial chemotherapy 
treatments are highly resistant, and differentiation treatment is required (Hara, 
2012). However, only 10 to 20 % of patients benefit from the actual differentiation 
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therapy, which consists of the administration of 13-cis-retinoic acid (Reynolds et 
al., 2003). For that reason, more effective, less toxic differentiation therapies must 
be developed.  
Increasing N2-Src expression in neuroblastoma cells would in principle 
induce differentiation in patients; however, this does not represent a simple 
therapeutic strategy. Targeting the neuronal splicing of Src would be complicated 
and require a deep understanding of the Src pre-mRNA splicing mechanism 
(Singh and Cooper, 2012). A similarly difficult approach would be to deliver N2-Src 
to neuroblastoma tumour cells. Nanoparticles or liposomes could be used as 
carriers fused to antibodies that recognise GD2, a membrane antigen 
overexpressed in neuroblastoma cells (Suzuki and Cheung, 2015). A more 
tractable approach would be to identify proteins whose inhibition would promote 
neuronal differentiation. COPII coat components or specific isoforms are potential 
target proteins, as well as specific cargoes. A deeper understanding of the role of 
COPII trafficking in neuroblastoma differentiation could therefore help in the 
development of new therapies. 
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Definitions and abbreviations 
3BP-1 β-galactosidase fusion protein 1 
ALK Anaplastic lymphoma kinase 
ATRX Alpha thalassemia/mental retardation syndrome X-linked 
BSA Bovine serum albumin 
CDKI Cyclin-dependent kinase inhibitor 
Chk Csk homologous kinase 
CK Casein kinase 
CNS Central nervous system 
COP Coat protein complex 
Csk Src specific kinase 
CUL3 Cullin 3 
KLH12 Kelch-like family member 12 
DAAM1 Dishevelled associated activator of morphogenesis 1 
DAPI 4,6-Diamidino-2-phenylindole 
DCS Downstream control sequence 
DMEM Dulbecco's modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
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EGTA Ethyleneglycoltetraacetic acid 
emPAI Exponentially modified Protein Abundance Index 
ER Endoplasmic reticulum 
ERES ER exit sites 
ERGIC ER-Golgi intermediate compartment 
ERK Extracellular signal regulated kinases 
EVL Enah/Vasp-like 
FAK Focal adhesion kinase 
FBS Fetal bovine serum 
FGF Fibroblast growth factor 
GABA Gamma-aminobutyric acid 
GAP GTPase-activating protein 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GRASP Golgi Reassembly stacking protein 
GTP Guanosine triphosphate 
HEK Human Embryonic Kidney 
HRP Horseradish peroxidase 
IGF Insulin-like growth factor 
IgG Immunoglobulin G 
iN2-Src Inducible N2-Src 
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IP Immunoprecipitation 
KSRP KH-type splicing regulatory protein 
LB Lysogeny broth 
LRRK2 Parkinson disease-related protein 
MAPK Mitogen-activated protein kinase 
RNA Ribonucleic acid 
miRNA microRNA 
mRNA Messenger RNA 
MYCN 
V-Myc avian myelocytomatosis viral oncogene neuroblastoma 
derived homolog 
NMDA N-Methyl-D-aspartate 
ORP1L Cytosolic oxysterol-binding protein 
PBS Phosphate-buffered saline 
PDGF Platelet-derived growth factor 
PHOX2B Paired-like homeobox 2b 
PI3K Phosphoinositide 3-kinase 
PTB Polypyrimidine binding protein 
PVDF Polyvinylidene difluoride 
RPMI Roswell Park Memorial Institute 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SFK Src family kinases 
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SH Src homology domain 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
TEMED Tetramethylethylenediamine 
TFB buffer Transformation buffer 
TFG TRK-fused gene 
TRAPPI Transport protein particle I 
Tris Tris(hydroxymethyl)aminomethane 
TrkA Tropomyosin receptor kinase A 
Ubp3/Brc5 
Ubiquitin-specific protease/ breast cancer type 5 susceptibility 
protein 
VAP VAMP-associated protein 
WAVE2 WASP-family verprolin-homologous protein 
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